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Abstract
This thesis project aimed to develop chimeric antigen receptors (CARs) capable of durably suppressing
the Human Immunodeficiency Virus Type 1 (HIV) replication, by building upon a previous CD4-based CAR
that was employed in several clinical trials. We applied lessons learned from cancer-targeting CARs to
optimize the CAR vector backbone, promoter, HIV targeting moiety, and transmembrane and signaling
domains, in an effort to determine which components augmented the ability of CD8 T cells to control HIV
replication. CD8 T cells expressing the optimized CARs were at least 50-fold more potent in vitro at
controlling HIV replication than the original CD4 CAR or TCR-based approaches and substantially better
than broadly neutralizing antibody-based CARs. We then utilized a humanized mouse model of HIV
infection to demonstrate superior control over HIV replication, better protection of CD4 T cells, and
greater CAR T cell expansion with the optimized vectors compared to the original clinical trial vector.
Compared to optimized CD4 CARs containing the CD28 costimulatory domain, CARs containing 4-1BB
expanded better in vivo in the absence of antigen and resulted in greater control over HIV replication. We
found that the CD4 CAR promoted infection of transduced CD8 T cells and employed CCR5 zinc finger
nucleases (ZFNs) or a GP41-based fusion inhibitor to protect the CAR T cells. We employed ZFNpretreated, CAR-transduced CD8 T cells in our mouse models and saw an enrichment of the disrupted
alleles in HIV-infected mice compared to mock controls. In humans, a functional cure will require CAR T
cells to prevent the spread of HIV following virus reactivation from the latent reservoir. We modeled this
scenario in vitro using ART patient T cells and latency reversing agents (LRAs). Preliminary data suggest
that CD4 CAR T cells can respond to low levels of antigen produced by resting ART patient cells in the
presence of LRAs. Together, these data indicate that potent HIV-specific T cells can be generated using
improved CAR design and provide optimism that CAR T cells could help achieve a functional cure.
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ABSTRACT
ENGINEERING CHIMERIC ANTIGEN RECEPTORS FOR DURABLE
CONTROL OVER HIV-1 REPLICATION

Rachel S. Leibman
James L. Riley

This thesis project aimed to develop chimeric antigen receptors
(CARs) capable of durably suppressing the Human Immunodeficiency Virus Type
1 (HIV) replication, by building upon a previous CD4-based CAR that was
employed in several clinical trials. We applied lessons learned from cancertargeting CARs to optimize the CAR vector backbone, promoter, HIV targeting
moiety, and transmembrane and signaling domains, in an effort to determine
which components augmented the ability of CD8 T cells to control HIV
replication. CD8 T cells expressing the optimized CARs were at least 50-fold
more potent in vitro at controlling HIV replication than the original CD4 CAR or
TCR-based approaches and substantially better than broadly neutralizing
antibody-based CARs.

We then utilized a humanized mouse model of HIV

infection to demonstrate superior control over HIV replication, better protection of
CD4 T cells, and greater CAR T cell expansion with the optimized vectors
compared to the original clinical trial vector. Compared to optimized CD4 CARs
containing the CD28 costimulatory domain, CARs containing 4-1BB expanded
better in vivo in the absence of antigen and resulted in greater control over HIV
replication.

v

We found that the CD4 CAR promoted infection of transduced CD8 T cells
and employed CCR5 zinc finger nucleases (ZFNs) or a GP41-based fusion
inhibitor to protect the CAR T cells.

We employed ZFN-pretreated, CAR-

transduced CD8 T cells in our mouse models and saw an enrichment of the
disrupted alleles in HIV-infected mice compared to mock controls.
In humans, a functional cure will require CAR T cells to prevent the spread
of HIV following virus reactivation from the latent reservoir. We modeled this
scenario in vitro using ART patient T cells and latency reversing agents (LRAs).
Preliminary data suggest that CD4 CAR T cells can respond to low levels of
antigen produced by resting ART patient cells in the presence of LRAs.
Together, these data indicate that potent HIV-specific T cells can be generated
using improved CAR design and provide optimism that CAR T cells could help
achieve a functional cure.
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CHAPTER 1 – Introduction: Engineering T cells to Functionally Cure HIV-1
Infection

Parts of this chapter were previously published in:
R. S. Leibman, J. L. Riley, Engineering T Cells to Functionally Cure HIV-1
Infection. Molecular therapy : the journal of the American Society of Gene
Therapy 23, 1149-1159 (2015).

Overview

Despite the ability of antiretroviral therapy (ART) to minimize Human
Immunodeficiency Virus Type 1 (HIV) replication and increase the duration and
quality of patients’ lives, the health consequences and financial burden
associated with the lifelong treatment regimen render a permanent cure highly
attractive. Although T cells play an important role in controlling virus replication,
HIV is adept at avoiding, destroying, and debilitating the naturally generated T
cell responses (1-3). Therefore, there is a need to develop HIV-specific T cells
with greater potency for use in HIV cure strategies.
Direct genetic manipulation of T cells for adoptive cellular therapies (ACT)
could facilitate a functional cure by generating HIV-1-resitant cells, re-directing
HIV-1-specific immune responses, or a combination of the two strategies (4). In
contrast to a vaccine approach, which relies on the production and priming of
HIV-1-specific lymphocytes within a patient’s own body, adoptive T cell therapy
provides an opportunity to customize the therapeutic T cells prior to
administration (Fig 1-1). However, after decades of research and advances in
1

the HIV cure and T cell immunotherapy arenas, it remains unclear how to best
engineer T cells so that sustained control over HIV-1 replication can be achieved
in the absence of antiretroviral therapy.

Infusing more HIV-1 specific T cells fails to control HIV-1 infection

Attempts to manufacture T cells as therapeutic agents to treat HIV have
been ongoing for over two decades.

After discovering the critical role that

cytotoxic T cells (CTLs) play in controlling HIV replication in vivo, researchers
sought to augment the activity of natural CTLs (5-8). When reinfusion of a single
expanded Nef-specific CTL clone led to virus escape, it became clear that
approaches that limited HIV escape would have to be employed, including more
broadly targeted CTL populations (9).

Along these lines, Lieberman et al.

expanded polyclonal HIV-specific CD8 T cells from patients by using autologous
B-LCL lines pulsed with a mixture of Env, Gag, and Nef peptides prior to
reinfusion. However, the decreases in plasma and cell associated virus were
minimal and not statistically significant at 24 weeks post infusion (10). Similarly,
Tan and colleagues infused two CTL clones that were rapidly eliminated upon
reinfusion, possibly due to an over-stimulated and overly-mature Fas+/CD28phenotype, exacerbated by the lack of CD4 T cell help (11). Toxicity concerns
then led to the incorporation of the hygromycin phosphotransferase–thymidine
kinase (HyTK) suicide gene, which would lead to cell death in the presence of
ganciclovir.

Riddell et al. selected Gag-specific CTLs and incorporated a
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retrovirally-delivered HyTK suicide vector; however, this evoked a CTL response
against the modified gene itself and elimination of infused CTLs (12).

To track

homing and persistence, Brodie et al. retrovirally modified Gag-specific CTLs to
express the neomycin phosphotransferase (neo) gene (13). Although a transient
decrease in productively infected cells in the lymph node was observed and neomarked CTLs were co-localized with HIV RNA+ cells in the lymph nodes, CTL
persistence declined rapidly. Together, these early studies highlight the difficulty
of engineering effective, safe, and sustained HIV-specific T cell therapies.

A case for gene therapy to treat HIV-1 infection

With 20 plus years of additional wisdom, it is interesting to consider why
these initial clinical trials failed to show durable control of HIV replication. For
one, the technology to expand T cells for adoptive T cell therapy was still in its
nascent stage and has subsequently improved significantly, accelerated by
success in cancer adoptive immunotherapy (14). Initial efforts to expand single
cells in the presence of high IL-2 levels over a period of months have evolved
into procedures that manufacture equivalent or higher numbers of cells over a
period of 10 days, with better engraftment potential and more robust effector
activity.

Technological advances in vector design have optimized transgene

expression by incorporating strong promoters, enhancer elements, nuclear
translocation signals, and post-transcriptional regulatory elements (15-17).
Conceptually, the field has a better understanding of the immunological
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challenges surrounding adoptive therapy for HIV.

It is now known that the

immune system makes a robust response to HIV infection, and HIV-specific CD8
and CD4 T cells can be readily identified in untreated, HIV-positive individuals
(18).

However, HIV has largely figured out how to evade the natural cell-

mediated immune response (1, 19, 20). Thus, the rationale to infuse more HIVspecific T cells is not as sound as the rationale to infuse better HIV-specific T
cells.

Specifically, T cells that persist in vivo, maintain cytolytic activity, and

target epitopes required for virus replication so that escape would be
accompanied by a decrease in viral fitness. Moreover, infusing billions of HIVspecific CD8 T cells without HIV-specific CD4 T cell help is akin to deploying
soldiers without the necessary supplies to sustain the fight.

There might be

some short-term benefit, but it is difficult to imagine how a war might be won with
this strategy. Unfortunately, rapid infection and depletion of these HIV-specific
CD4 T cells negates and complicates the benefits of infusing CD4 T cells to
support CD8 cytolytic effector functions (3).

Redirecting polyclonal T cells to target HIV-1

Once the propensity for CTL-induced virus escape was established in the
early adoptive therapy trials, researchers next sought to improve upon the natural
cell-mediated cytotoxic responses by engineering artificial antigen receptors.
Conceptually, these receptors have advantages over traditional TCRs in that they
can be affinity enhanced to exhibit broader epitope reactivity or can be designed
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to bind intact, non-processed viral proteins, similarly broadening the scope of
HIV-specific CTL antigens. Importantly, these receptors need to be designed to
target sequences from which escape leads to a significant loss of viral fitness.

Affinity enhanced TCRs for adoptive T cell therapy

Joseph and co-workers demonstrated that polyclonal CD8 T cells could be
redirected to target HIV-infected cells upon transduction with a lentivirus
expressing the HIV Gag-specific SL9 TCR, which recognizes an HLA-A*02
restricted Gag epitope SLYNTVATL (A2-SL9) and is associated with lower
plasma virus levels during chronic HIV infection (21). These cells lysed A2-SL9expressing target cells and were able to greatly reduce HIV infection in a SCID
mouse model of HIV infection.

The low inherent affinity of TCRs for their peptide-MHC binding partners,
in the general range of 1-100µM, led researches to hypothesize that enhanced
TCR binding affinity could lead to more powerful and sustained CTL responses
(22). Affinity enhancement was invoked successfully to modify the HLA-A*01
restricted TCR specific for the NY-ESO-1 testes-specific tumor antigen. In early
clinical trials, 5/11 melanoma patients and 4/6 synovial cell sarcoma patients
experienced complete or partial responses to NY-ESO-1 TCR-transduced T cell
infusions (23). Varela-Rohena et al. reported a similar method to enhance the
A2-SL9 TCR, producing a TCR with picomolar affinity for its cognate antigen that
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could control both CCR5- and CXCR4-utilizing strains of HIV better than the wildtype (WT) A2-SL9 TCR (24). Furthermore, the enhanced affinity TCR produced
higher levels of the cytokines IL-2, MIP-1β, and IFNγ in response to A2-SL9expressing K562 artificial antigen presenting cells (aAPCs) and could control
common SL9 escape variants not recognized by WT SL9 TCR. A clinical trial
(NCT00991224) was initiated to examine the effects of infusing WT or affinity
enhanced SL9 TCR-transduced T cells in HIV-infected patients.

Unfortunately, off-target toxicity that resulted in the death of two
participants in a different trial with an affinity-enhanced HLA-A*01 restricted
MAGE-A3-specific TCR for myeloma and melanoma patients caused concern
over the ability of investigators to predict and model the target specificity of
affinity enhanced TCRs (25). In the MAGE-A3 trial, the high affinity TCRs gained
the capacity to bind an epitope from the unrelated protein titin, expressed on
contracting cardiac tissue, and resulted in cardiac toxicity(26). As this protein is
only expressed on beating cardiomyocytes and not traditionally cultured cardiac
myocytes, this off-target killing capacity was not identified in preclinical toxicity
tests. The results of this trial underscored the need for thorough pre-clinical
bioinformatics screening to identify all proteins containing the minimal amino acid
sequences required for TCR recognition (26), combined with sophisticated cell
culture techniques to identify off-target CTL reactivity to these proteins. After
careful discussions with the NIH, FDA, and IRB, NCT00991224 was closed
before any patient received T cells transduced with a high affinity A2-SL9-specific
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TCR.

The use of T cells expressing high affinity TCRs to target HIV, and

particularly the HIV reservoir, is still an attractive concept, predicated upon a
better understanding of the safety and specificity of these approaches.

Chimeric antigen receptors for adoptive therapy

Chimeric antigen receptors (CARs) are hybrid antigen receptors in which
an extracellular antigen binding domain is linked to intracellular T cell activation
domains, most commonly the CD3 zeta chain (27-29). More recently, secondand third-generation CARs have been developed by including additional
costimulatory domains such as 4-1BB and/or CD28 to increase proliferation and
survival of modified cells (16, 30, 31). Unlike a TCR, where antigen binding is
physically uncoupled from signal transduction, CARs accomplish both of these
functions from a single protein (Fig 1-2).

While this limits the repertoire of

potential targets to surface expressed proteins, it allows T cells to bind targets in
a high affinity, TCR-independent, MHC-unrestricted manner.

Unlike TCRs,

CARs avoid the potential danger of mispairing with endogenous alpha and beta
chains to generate off-target specificities and do not compete with TCRs for
limited levels of endogenous CD3 complexes (27). CARs have been employed
successfully for cancer adoptive therapy, mediating remission in approximately
80% of acute lymphocytic leukemia patients (32-34), and development for use in
solid tumors is well under way (35, 36).
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CARs that bind the HIV Envelope (Env) glycoprotein, which is expressed
on the surface of virions and HIV-infected cells, have been created using HIVspecific antibody single-chain variable fragments or the host protein CD4 as the
antigen binding moieties (37-39). Pre-clinical experiments determined that CARtransduced CD8 T cells specifically lysed Env-expressing cells in vitro, and a
gammaretroviral vector incorporating the CD4-based CAR entered four clinical
trials (40-43). Despite the possibility that surface expression of CD4 from the
CD4 CAR could render transduced CD8 T cells susceptible to infection, the
persistence of CAR T cells was striking, with the modified cells detectable in 98%
of samples tested up to 11 years post infusion (43).

Linear mixed-effects

modeling predicted a decay rate of over 16 years, with gene expression in 11/13
patients. This persistence was speculated to be the result of culture methods
that resulted in a high proportion of central memory cells, combined with
expression of a non-immunogenic transgene that may have been intermittently
stimulated in vivo through low affinity interactions with MHC class II molecules or
HIV Env due to bursts in virus replication (43). The low affinity of CD4 for MHC
class II likely prevented modified cells from attacking normal host cells (44).
Although CAR-transduced cells could not be sorted in the post-infusion patient
samples due to the inability to distinguish the CAR CD4 from endogenous CD4,
patient PBMCs were stimulated with anti-CD4 loaded K562 aAPCs and zeta
chain copy number was found to increase, suggesting the ability of CAR T cells
to proliferate in response to antigen (43). While none of the clinical trials led to
durable reductions in viral loads, an important outcome of these trials was the
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lack of related serious adverse events, indicating the safety of utilizing
gammaretroviral vectors for T cell directed gene therapy approaches. Moreover,
the prolonged persistence of the transduced cells is promising, as earlier T cell
infusion trials led to much more rapid decay rates. Thus, we hypothesized that
with the proper technological advances, CAR T cell expansion and functionality
could be improved to facilitate sustained control over HIV replication.

Dissertation research

Considering that almost all of the major advances in ACT with CARs have
been made for cancer-targeting CARs, it is interesting that the first CAR to reach
the clinic was an HIV-targeting CAR. Over the past 15 years, major technical
advances in ACT have been realized, both in T cell growth and transduction
procedures, and improved CAR design (14, 45). We therefore sought to apply
lessons learned from key oncology CAR studies to enhance HIV-targeting CARs
in a systematic approach.
This thesis was designed to determine what components of CARs are
critical for control over HIV replication in vitro and in vivo. We maintained the
hypothesis that a redesigned CAR which exhibited a greater cytotoxicity profile in
vitro could be revisited as a critical component of an ACT-based HIV cure
strategy. We took a stepwise approach to optimize the CAR expression levels as
well as the structural and functional features of the CD4 CAR.

We asked

whether the CARs that functioned best in vitro similarly controlled HIV in
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humanized mice. This research will be discussed in Chapter 2. During these
experiments, it became apparent that the CD4 CAR rendered T cells expressing
this construct susceptible to HIV infection, regardless of being a CD4 or a CD8 T
cell.

Chapter 3 explored the outcome of protecting these T cells from HIV

infection and is an ongoing area of research in the lab.

Finally, we asked

whether we could model the latent reservoir to gain insight into the possibility of
CARs facilitating a functional cure in HIV patients.

This research will be

discussed in Chapter 4.
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Figure 1-1. Overview of adoptive T cell therapy. Adoptive T cell therapy (ACT) is the
process of removing patients’ peripheral blood mononuclear cells (PBMCs), isolating the
T cells, and modifying them for therapeutic purposes prior to returning to the patient.
The T cells are typically activated and expanded to augment their functionality prior to
reinfusion. Additionally, antigen-specific cells (which respond to cancer or target
peptides) can be selected for. More recently, T cells have been modified to express T
cell receptors (TCRs) or chimeric antigen receptors (CARs) to redirect polyclonal T cells
to target a specific antigen. Schematic taken from Sharpe, M. and Mount, N. 2008.
Disease Models & Mechanisms.
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Figure 1-2. Comparison of T cell receptor (TCR) and chimeric antigen receptor
(CAR) structure. A TCR is comprised of the αβ heterodimer, which is responsible for
binding to the complex of antigenic peptide presented by major histocompatibility
complex (MHC) molecules, in complex with various CD3 signaling chains which transmit
intracellular activation signals. Various costimulatory molecules including CD28 and 41BB or OX40 can localize near the TCR and participate in cellular activation. In
contrast, a CAR fuses the extracellular antigen binding domain, typically a single chain
variable fragment adapted from an antibody, directly to the CD3 zeta T cell activation
domain. Additional intracellular costimulatory domains, taken from CD28, 4-1BB, OX40,
among others, can be included within the intracellular portion of the CAR. Binding
Schematic adapted from Gao, J. et al. 2008. Trends in Immunology.
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CHAPTER 2 – Supraphysiologic control over HIV replication mediated by
CD8 T cells expressing a re-engineered CD4-based chimeric antigen
receptor

Abstract
HIV is adept at avoiding naturally generated T cell responses; therefore,
there is a need to develop HIV-specific T cells with greater potency for HIV cure
strategies. Starting with a CD4-based chimeric antigen receptor (CAR) that was
previously used safely in humans, we optimized the vector backbone, promoter,
HIV targeting moiety, and transmembrane and signaling domains to determine
which components augmented the ability of T cells to control HIV replication.
This re-engineered CAR was at least 50-fold more potent in vitro at controlling
HIV replication than the original CD4 CAR, or a TCR-based approach, and
substantially better than broadly neutralizing antibody-based CARs. A
humanized mouse model of HIV infection demonstrated that T cells expressing
optimized CARs were superior at promoting CAR T cell expansion, protecting
CD4 T cells, and reducing viral loads compared to the original, clinical trial CAR.
Moreover, in a humanized mouse model of HIV treatment, CD4 CAR T cells
containing the 4-1BB costimulatory domain controlled HIV spread after ART
removal better than analogous CAR T cells containing the CD28 costimulatory
domain. Together, these data indicate that potent HIV-specific T cells can be
generated using improved CAR design and that CAR T cells could be important
components of a HIV cure strategy.
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Introduction

It is well established that T cells play an important role in controlling HIV-1
(HIV) replication, and that HIV-infected individuals develop robust HIV-specific T
cell responses (6, 18). However, HIV evades the endogenous T cell-mediated
immune response by altering key residues required for T cell recognition and
downregulating class I major histocompatibility complexes (MHC) (1, 2).
Additionally, HIV-mediated depletion of HIV-specific CD4 T helper cells and the
chronic persistence of the virus functionally impair HIV-specific CD8 T cells so
that, in most individuals, T cells are unable to control HIV replication (3).
Although antiretroviral therapy (ART) can suppress HIV replication by many
orders of magnitude, it fails to eliminate the virus, forcing HIV-infected individuals
to be treated by ART regimens for the rest of their lives. ART also reduces the
number of HIV-specific T cells present, due to a massive reduction in HIV
antigen, and the T cells that remain often have functional defects (46, 47). Thus,
at the time of ART removal when the number of HIV producing cells is minimal,
the resident HIV-specific T cell immune response is ill-equipped to control the reemerging infection and uniformly fails, with viral loads returning to patient-specific
set point within weeks after ART removal (48). As a result, we and others have
postulated that instead of relying on the endogenous immune response to control
HIV replication as part of an HIV cure strategy, the introduction of a potent
engineered immune response designed to overcome HIV’s escape mechanisms
will be required to provide durable control HIV in the absence of ART (49-51).
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Previous ACT trials have demonstrated that simply reinfusing expanded
patient T cells does not result in durable control over HIV replication (49). Thus,
both the quality and quantity of infused HIV-specific T cells must be enhanced for
a sustained therapeutic benefit. Attempts to manufacture better T cells for ACT
have recently been made through antiviral transgenes, coreceptor editing, and
redirecting T cells with HIV-specific T cell receptors (TCRs) or chimeric antigen
receptors (CARs) (4, 49). CARs consist of an extracellular antigen binding
domain fused to intracellular T cell activation domains (52). These synthetic
receptors can redirect T cells to recognize viral proteins independent of antigen
processing, TCR, and MHC. CARs targeting CD19 have revolutionized the
treatment of leukemia and lymphomas through their ability to persist and
maintain durable anti-tumor effects in vivo (53, 54). Of note, the first CAR to
enter human trials redirected T cells to target the GP120 region of the HIV
Envelope (Env) glycoprotein (40-42). This was achieved by fusing the
extracellular and transmembrane domains of CD4, the cellular receptor for HIV,
to the CD3-zeta cytoplasmic region (CD4-zeta). HIV-specific cytotoxicity was
established in vitro, and safety was demonstrated in vivo, with transient
reductions in HIV RNA, DNA, and quantitative HIV outgrowth assays (37, 39, 41,
42, 55). A long-term follow up study determined the half-life of the CAR-modified
cells to be over 16 years, with CAR expression up to 10 years post infusion and
no serious adverse events (43). However, the CD4-zeta CAR did not lead to
sustained reductions in viral loads or the viral reservoir, and the clinical data were
not sufficiently promising to warrant additional development.
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Subsequent to the HIV CAR clinical trials, a number of advances have
been made in CAR design for optimal antitumor responses. Xenograft models
and clinical trials have established that costimulation augments function,
proliferation, and survival in vivo (16, 56, 57). In addition, CAR structural and
signaling domains have been found to greatly impact T cell function and
susceptibility to exhaustion (58, 59). For example, it was recently demonstrated
that CAR costimulatory domains influence T cell metabolic and phenotypic
profiles, with 4-1BB promoting a central memory phenotype and CD28 promoting
an effector memory phenotype (60). While there has recently been a renewed
interest in utilizing CARs to control HIV, including efforts to increase CAR T cell
function and survival, a systematic optimization of CAR T cell cytotoxicity was
lacking (61, 62). We sought to apply the lessons learned from engineering CARs
for hematologic malignancies to optimize the CD4 CAR for superior control over
HIV replication. We demonstrate here that changing the CAR expression vector,
promoter, transmembrane, and costimulatory domains improved control over HIV
in vitro by over 50-fold. In vivo, humanized mice engrafted with T cells
expressing these optimized vectors had significantly higher CD4 T cell counts,
greater CAR+ CD8 T cell proliferation after HIV infection, and 90% less HIV RNA,
compared to mice that received T cells transduced with the clinical trial CD4-zeta
CAR. An HIV treatment model demonstrated superior control over HIV
replication by 4-1BB containing CARs, compared to equivalent CARs containing
the CD28 costimulatory domain. These data provide a compelling reason to
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revisit human clinical trials with CD4 CARs that have been optimized for control
over HIV in vivo for use in HIV cure studies.
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Results

Lentiviral backbone augments CAR expression and control over HIV
replication. Preclinical studies testing the original CD4-zeta CAR showed that T
cells expressing this construct had equivalent antiviral activity to naturally
generated HIV-specific T cells (55). We hypothesized that the reason these
clinical trials failed to demonstrate durable clinical responses was that the T cells
used in these trials were no more potent than the endogenous HIV-specific T cell
response. Therefore, we sought to optimize the CD4-zeta CAR based on
lessons learned from cancer-specific CARs to augment control over HIV
replication (14). To do this, we optimized each component of the CAR in a stepby-step manner. We first addressed to what extent the vector backbone
contributes to the ability of CAR+ CD8 T cells to control HIV. The original CD4zeta CAR was expressed by a murine retroviral vector (MMLV-based). Since
MMLV-based vectors target promoter regions and lentiviral vectors (HIV-based)
integrate preferentially into open reading frames, we reasoned that lentiviral
vectors would result in higher expression than MMLV-based vectors (63). We
generated the MMLV clinical trial construct and an analogous lentiviral vector,
both with the PGK promoter, and transduced primary human CD8 T cells.
Lentiviral transduction consistently resulted in a ~10-fold higher median
fluorescence intensity (MFI) of CAR expression compared to MMLV retrovirus
(Fig 2-1 A-D). To determine whether the higher transgene expression was the
result of more vector integrations per cell, we measured the integrated vector
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copy number in the different T cell populations using a previously established
assay (43). We found that the MMLV-based vector had almost twice the number
of integrations compared to the HIV-based vector (Fig 2-1 E), indicating that the
higher transgene expression of the HIV-based vector is due to its intrinsic
properties.
A co-culture assay was used to compare the different CARs in terms of
their ability to control HIV replication (Fig 2-1 F). In this assay, HIV-infected CD4
T cells were cultured with either nontransduced (NTD) CD8 T cells or CAR
transduced CD8 T cells, and the ability of the effector CD8 T cells to control HIV
spread was measured over 7-14 days. To distinguish between HIV spread
throughout the CD4 T cells and infection of the CD4 CAR+ CD8 T cells, we gated
separately on the CD8 negative and the CD8 positive T cells, and then analyzed
intracellular p24 (Gag) in CD4 T cells and CD8 T cells, respectively (see gating
strategy in Fig 2-2). High levels of HIV replication were observed in CD4 T cells
co-cultured with NTD CD8s (Fig 2-1 G). In contrast, CD8 T cells transduced with
either a MMLV-based or HIV-based CAR vector were able to control HIV
replication at a 1:1 E:T ratio, similar to what was observed in previous studies of
this strategy (37, 39, 55). However, upon diluting the CAR transduced CD8 T
cells to lower E:T ratios, T cells transduced with the HIV-based vector were
superior at controlling HIV replication over time (Fig. 2-1 G-J). Ultimately, neither
population of transduced CD4 CAR CD8 T cells could control HIV spread at a
1:50 E:T ratio.
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In contrast to recent reports that CD4 CAR transduced CD8 T cells are
susceptible to infection by cell-free virus (61, 62), we were only able detect
intracellular Gag in CAR+ CD8 T cells after diluting to low E:T ratios with HIVinfected CD4 T cells (Fig 2-1 H, Fig 2-3). Of note, there was a small proportion
of nontransduced CD8 T cells that stained positively for Gag, regardless of the
E:T ratio. This was likely the result of the ability of CD8 T cells to transiently
express CD4 after activation (64-67). This data highlights the complex
relationship between CD4 CAR expression and susceptibility to HIV infection. At
high E:T ratios the CAR+ CD8 T cells are able to fully suppress HIV replication,
and thus they and the co-cultured CD4 T cells are protected from HIV infection.
However, at low E:T ratios, the CAR+ CD8 T cells are no longer able to suppress
HIV replication, and the virus is able to spread throughout both populations of
cells (Fig 2-1 H).

EF1α promoter and CD8α transmembrane domains improve CAR
expression and control over HIV. Transgene expression in T cells wanes
when driven by the PGK promoter as T cells rest down. In contrast, the EF1α
promoter induces higher expression that is better sustained as T cells return to
quiescence (16). We hypothesized that the EF1α promoter might be beneficial in
our system, since greater CAR MFI expression correlated with better control over
HIV (Fig 2-1). Under the EF1α promoter, CAR expression MFI increased ~10fold compared to the PGK promoter (Fig 2-4 A and B). Next, we substituted the
CD8α transmembrane (TM) domain in place of the CD4 TM domain to promote
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CAR dimerization, remove CD4 TM motifs targeted by HIV Vpu for
downregulation, decrease homology to the HIV cellular receptor, and ultimately
augment cytotoxicity (68-71). Greater control over HIV replication was achieved
by both modifications individually, and a combination of the two modifications led
to complete control over HIV replication down to a 1:50 E:T ratio (Fig 2-4 C and
E). Substitution of the CD8α TM domain decreased infection of CAR CD8 T cells
regardless of the promoter used at the 1:25 and 1:50 E:T ratios (Fig 2-4 D). We
observed similar results when examining the culture supernatants for p24 Gag
(Fig 2-5). However, as seen in Fig 2-1 and Fig 2-3, the CAR+ CD8 T cells could
be diluted to the point where they no longer controlled HIV infection and
succumbed to infection themselves (Fig 2-4D). To ensure this was not an
artifact of gating on a few CD8 T cells, we performed a larger scale experiment
where at least 1x104 CD8 T cells were collected per condition and the infection
pattern was the same (Fig 2-6). Thus, altering the viral vector, promoter, and
transmembrane domains afforded a 50-fold increase in potency over the clinical
trial MMLV-based retrovirus, resulting in complete control over HIV replication at
a 1:50 E:T ratio in vitro (Fig 2-4 E and F).

Re-directed T cells expressing a CD4 CAR are 100-fold more potent than redirected T cells specific for B57-KF11. Elite controllers are rare individuals
who control HIV replication in the absence of ART. Certain HLA alleles, such as
HLA-B57, are overrepresented in these cohorts, suggesting that T cell responses
play a key role in controlling their virus (72). Therefore, we wished to determine
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whether T cells expressing a re-engineered CD4 CAR (with the EF1α promoter
and CD8α TM) could control HIV replication better than T cells expressing a
HLA-B57 restricted TCR that is associated with better control over HIV
replication. To do this, we generated an analogous lentiviral vector that
expressed the TCRα and TCRβ chain under the EF1α promoter to confer
specificity for B57-KF11 epitope (HIV p24 Gag epitope KAFSPEVIPMF) (Fig 2-7
A). To confirm these cells recognized Gag-expressing cells, we incubated them
with target CD4 T cells from HLA-B57+ individuals that were transfected with Gag
RNA, or Pol RNA as a negative control, and detected a robust Gag-specific
cytokine response (Fig 2-7 B). Next, we compared the ability of KF11 TCR
versus CD4 CAR transduced CD8 T cells to limit HIV spread in HLA-B57 CD4 T
cells. While KF11 TCR-transduced CD8 T cells reduced HIV replication down to
a 1:25 E:T ratio, complete control over HIV replication was never achieved (Fig
2-8). In contrast, the re-engineered CD4 CAR controlled HIV almost completely
down to a 1:100 E:T ratio. These data suggest that the synthetic CD4 CAR
approach is more potent than the natural TCR based approach and that the CD4
CAR approach will likely be more effective as a cellular therapy tool compared to
T cells transduced with a patient-derived, natural TCR.

CD4-based CARs control HIV more effectively than broadly neutralizing
antibody-based CARs. The most commonly used CAR ectodomains are
antibody-derived single chain variable fragments (scFvs) (52). Over the past
several years, a number of HIV-specific antibodies have been described that bind
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or neutralize HIV with high affinity and/or target a wide breadth of viruses (73).
We tested whether the use of scFvs to redirect T cells to HIV was superior to the
use of CD4. In addition, we wanted to test whether CD8 T cells expressing scFvbased CARs were less susceptible to HIV infection than CD4-based CARs. A
panel of scFvs derived from the VRC01, 3BNC60, PG9, PGT128, or PGDM1400
parental antibodies were generated due to their neutralization breadth and/or
potency against HIV and cloned into the most effective CAR design identified in
Fig 2-4, with the EF1α promoter and the CD8α TM domain (74, 75). To
determine that each scFv CAR had folded properly, could interact with Env, and
promote CD8 T cell lysis, we measured specific lysis of chromium labeled K562
target cells expressing the Env protein from the HIV YU2 strain. All CARs were
capable of lysing Env-expressing targets to a similar degree, indicating that these
CARs recognized HIV Env (Fig 2-9 A). Many of the scFv CARs consistently
produced higher levels of intracellular cytokines in response to Env-expressing
targets when compared to the CD4 CAR (Fig 2-10 A). However, when cocultured with HIV-infected CD4 T cells, the CD4 CAR controlled HIV better than
all of the scFv-based CARs (Fig 2-9 B and D, and Fig 2-10 B). Interestingly, the
PGT128 CAR repeatedly controlled HIV better than the other scFvs tested,
despite being less broad and less potent in neutralization studies than
PGDM1400 (75). Surprisingly, at low E:T ratios we detected high levels of
intracellular Gag in the scFv CD8 T cells, similar to CD4 CAR+ T cells diluted to a
1:200 E:T (Fig 2-9 C). This was not a byproduct of lentiviral transduction or
generic CAR expression, as this was not seen for GFP-transduced or CD19
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CAR-transduced cells (Fig 2-10 C) and thus appears to depend on HIV binding
ability, possibly concentrating the virus near the CAR-transduced cell membrane.
Based on the in vitro superiority of the CD4 CAR against this limited scFv subset,
and the inherent difficulty of HIV escaping from CD4 binding, we chose to pursue
development of CD4-based CARs for in vivo testing.

ICOS, CD27, and 4-1BB costimulation impair control of HIV replication in
vitro. T cells require costimulatory signals for proliferation, effector function, and
long-term survival (76). Costimulatory domains, such as CD28 and 4-1BB, have
been incorporated into recent CAR designs for durable CAR T cell responses in
vivo (56). In chronic HIV infection, T cell dysfunction and exhaustion have been
well documented, and decreased CD28 and 4-1BB signaling impair cytolytic and
effector function (47, 77, 78). Therefore, we generated a panel of CD4 CARs
that incorporated a variety of costimulatory domains in conjunction with the CD3zeta domain, including CD28, 4-1BB, CD28+4-1BB, OX40, ICOS, or CD27 and
tested their ability to control HIV infection in vitro. CD8 T cells expressing CARs
that contained 4-1BB, CD27, or ICOS costimulation domains did not control HIV
as effectively as T cells expressing CARs that expressed the other costimulatory
domains, suggesting that these costimulatory pathways interfered with control of
HIV replication (Fig 2-11). Regardless of the costimulatory domain, the control
seen with these CD4 CARs was superior to the control seen with an HIV-specific
TCR (Fig 2-8) or with scFv based CARs (Fig 2-9). While CD28 promoted better
control over HIV in vitro compared to 4-1BB, discrepanices between the in vitro
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and in vivo activity of cancer-specific CARs containing 4-1BB had been reported
(58, 60). Thus, we were curious if this held true for HIV-specific CARs, and
decided to further characterize the safety profile and in vivo efficacy of CD4
CARs expressing either CD28 or 4-1BB.

CD4 CARs respond to Env+ cells and not MHC class II+ cells. Preclinical data
demonstrated that T cells expressing the clinical trial CD4-zeta CAR did not kill
Raji cells, which express high levels of MHC class II, the low affinity ligand of
CD4 (39). However, we were concerned that our optimized, highly expressed
CD4 CAR might recognize MHC class II expressing cells. To test this, we
measured CAR+ CD8 T cell responses against K562 cells stably expressing high
levels of the HLA-DR*0401 allele (Fig 2-12). CD8 T cells were transduced with
optimized CD4 CARs containing CD3-zeta alone or with the 4-1BB and CD28
costimulatory domains and cultured with unmodified K562 target cells, HLADR*0401+ K562 cells, or HIV YU2 Env+ K562 cells. CAR transduced CD8 T cells
produced IL-2, CD107a, IFN-γ, and MIP-1β in response to HIV Env+ targets but
not in response to HLA-DR+ or parental K562s, with the most robust production
by CD28-containing CAR T cells (Fig 2-13 A). A small MIP-1β signal was
observed for all CARs mixed with parental or HLA-DR expressing targets that
was not observed with NTD controls, likely due to some constitutive signaling
observed in CAR T cells (79). It has been shown that autocrine production of
beta chemokines by CMV-specific T cells decreases CCR5 expression and
protects these cells from HIV infection, so this low-level MIP-1β production may
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help protect the CAR+ CD8 T cells in vivo (80). Importantly, no difference in
cytokine or CD107a production was detected by CAR T cells cultured with
parental versus MHC class II expressing cells, suggesting that our optimized
CD4 CARs do not facilitate off-target recognition of MHC class II. Coculturing the
optimized CD28-containing CAR with HLA-DR+ K562 cells over an extended
period further confirmed the lack of off-target responses. We mixed HLA-DR+
K562 cells 1:1 with HLA-A2+ K562 control cells and did not see a change in the
ratio of the two K562 populations over time (Fig 2-13 B and C), suggesting that
the re-engineered CAR will exhibit a similar safety profile in humans as the
original CD4 CAR.

Optimized CAR T cells control HIV replication better and expand to greater
levels in vivo than first generation CAR T cells. CD19-specific CARs
containing the CD28 signaling domain had superior in vitro activity than those
containing the 4-1BB signaling domain, but the 4-1BB containing CARs proved
superior in humanized mouse models and in patients (16, 54, 81). We wished to
determine whether the same was true for HIV-targeting CARs. In addition, we
wanted to determine if our optimized CD4 CARs could control HIV better in vivo
then the original CD4-zeta CAR that was tested in the clinic. To do this, we
utilized a NSG humanized T cell (NSG hu-T cell) mouse model. In this model,
detectable T cell engraftment (>10 cells per µl of blood) takes 2-3 weeks, and
over the next 2-3 months T cell engraftment slowly rises until the mice become
sick due to xenograft-mediated GVHD (82, 83). HIV infection prevents CD4 T
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cell expansion and, paradoxically, makes the animals healthier. Thus, evidence
of GVHD and high levels of CD4 T cell engraftment are strong evidence that antiviral agents, such as CAR T cells in this case, are effective. Four groups of mice
were compared with different CD8 effector cell populations: nontransduced
(NTD), transduced with the optimized lentiviral vector containing either 4-1BB
(BBz) or CD28 (28z) costimulatory domains, or transduced with the clinical trial
MMLV-based vector (MMLV-CD4z). Pre-infection, baseline CD4 T cell counts
did not differ significantly between the NTD, BBz, or 28z groups, and were
significantly higher for the MMLV-CD4z treated mice (Fig 2-14 A). After HIV
infection, we observed that mice infused with T cells expressing the BBz or 28z
construct had a 17-fold and 177-fold expansion of the number of human CD4 T
cells, respectively (Fig 2-14 B). In contrast, endpoint CD4 counts were depleted
in NTD or MMLV-CD4z mice (Fig 2-14 B). Examination of the number of CAR+
CD8 T cells in the different mouse cohorts revealed 389-fold, 587-fold, and 2-fold
expansions in the BBz, 28z, and MMLV-CD4z T cells, respectively (Fig 2-14 C
and D), suggesting there is a correlation between the ability of CAR T cells to
expand and the ability to protect CD4 T cells from HIV-mediated destruction.
We also examined viral loads. Since HIV replication is highly dependent
on the number of CD4 T cells present in this model, we normalize viral load to
the number of CD4 T cells present at a given timepoint to fairly compare different
treatment groups. Seven days following HIV infection, BBz CAR T cells exhibited
the greatest control over virus replication, with many mice showing undetectable
virus loads, whereas plasma from NTD, 28z, and MMLV-CD4z treated animals
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contained approximately 1 normalized copy of HIV RNA per µl (Fig 2-14 E).
Eighteen days post infection, the median copy number of HIV RNA was reduced
by more than 10-fold in both BBz and 28z treatment groups, compared to the
mice that were treated with NTD T cells (Fig 2-14 F). However, MMLV-CD4z
treated mice has similar HIV RNA loads as NTD treated mice. Thus, the
optimized CARs are superior at protecting CD4 T cells, promoting CD8 T cell
expansion, and controlling HIV replication in vivo, with BBz CARs superior in
preventing the early spread of HIV.

CAR T cells containing 4-1BB outperform CAR T cells containing CD28 in
an HIV-treatment model. After establishing that optimized CARs can function in
humanized mice to control HIV replication, we next wanted to model CAR
treatment of pre-established HIV infections and further examine whether 4-1BB
or CD28 costimulation promoted better in vivo control. To mimic how CARs
would be applied in a clinical trial, we injected CAR T cells into NSG mice with a
previously established pool of HIV-infected T cells in the presence of ART and
monitored virus rebound after ART was stopped (Supplementary Fig 2-15).
After three days of HIV infection in the presence of ART, the peripheral
blood CD4 T cell counts were similar for all groups (Fig 2-16 A). However, at 18
days post ART removal CD4 T cell depletion was apparent in NTD and 28z CAR
treated mice, with significantly higher CD4 T cell counts in the BBz treatment
group (Fig 2-16 B). By the endpoint bleed, the 28z CARs demonstrated
increased protection of CD4 T cells, and only the NTD mice had significantly
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lower CD4 T cell counts (Fig 2-16 C). In contrast, mock infected mice
maintained similar CD4 T cell counts in all treatment groups at all timepoints
(Supplementary Fig 2-16 A-C). Interestingly, endpoint CD4 T cell counts were
similar in this experiment for both BBz and 28z CAR treatment groups (Fig 2-16
B and C), as opposed to Fig 2-14 where CD4 counts were significantly higher in
28z treated mice. Ten days post ART removal, the CAR treated mice had higher
peripheral blood CD8 T cell counts compared to NTD mice (Fig 2-16 D). This
effect was HIV-specific, as all mock treated mice had similar CD8 T cell counts
(Fig 2-17 D). However, by 18 days post ART removal the CD8 T cell counts
were significantly higher in mice that received BBz CARs compared to NTD or
28z CAR-treated mice (Fig 2-16 E and F). This BBz CAR proliferation effect was
partially antigen independent, as greater BBz CAR expansion was also seen in
mock treated mice (Fig 2-17 E and F), consistent with the notion that 4-1BB
signaling in tumor-specific CARs promotes T cell survival (16, 58, 84)
Prior to CD8 T cell injection, while the animals were on ART, most mice
had undetectable viremia and 3/20 had very low levels of plasma HIV RNA (<1
copy per ul, Table 2-1). Ten days post ART removal, all NTD mice had
detectable plasma RNA, whereas all CAR treated mice had very low or
undetectable HIV, as measured by plasma HIV RNA (Fig 2-16 G). Similar
patterns of control were detected via measuring plasma HIV p24 Gag protein
using an ultrasentive assay (Fig 2-18). However, after 18 days post ART
removal, 28z treated mice experienced an increase in HIV replication and had
similar plasma levels of HIV as NTD mice, whereas the BBz mice maintained
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significantly better control (Fig 2-16 H, I and Fig 2-18 B). Together, these data
suggest that a CD4 CAR containing the 4-1BB zeta signaling domain will be most
effective in HIV cure strategies because 1) its ability to act rapidly to prevent HIV
spread (Fig 2-14 E and F), 2) its ability to durably prevent viral rebound (Fig 2-16
H and I), and 3) its ability to promote T cell survival in the absence of antigen
(Fig 2-17 E and F).
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Discussion

T cell control over virus replication is enabled through potent effector
mechanisms that ensure rapid killing and prevent dissemination of progeny
viruses (85). However, HIV employs multiple strategies to evade T cell
recognition and control. For instance, the HIV Nef protein modulates expression
of MHC class I, CD28, and other proteins involved in immune recognition to
evade cytotoxic T lymphocytes (CTL) (2, 86). Additionally, the phenomenal
capacity of HIV to modify its MHC class I restricted peptide antigens promotes
escape from CTL responses (1). Moreover, due to chronic HIV persistence,
CTLs become exhausted and progressively lose their effector functions (47). For
these reasons, there is a strong rationale to develop HIV-specific T cells with
enhanced, supraphysiologic ability to control HIV replication for therapeutic
studies aimed to establish long-term control, or a “functional cure,” in the
absence of antiretroviral treatment.
We hypothesized that we could re-engineer the original CD4 CAR that
was tested in the clinic and determined to be safe and long lived, but lacked
potent antiviral activity, to develop T cells that were far more effective in
controlling HIV infection (40-42). We found that switching from a MMLV-based
gammaretroviral vector to an HIV-based lentiviral vector resulted in much higher
CAR surface expression, and expression was further augmented upon
substituting the EF1α promoter for than the PGK promoter, consistent with
previous cancer-targeting CAR studies (16). Higher CD4 CAR expression in
primary human CD8 T cells correlated with improved control over HIV replication.
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However, this was not a perfect correlation, as incorporating the CD8α TM
domain rather than CD4 TM domain resulted in lower CAR expression but
improved control over HIV replication. We favor two non-mutually exclusive
explanations of this finding: the CD8α TM domain facilitates less HIV fusion than
the CD4 TM domain, making cells less susceptible to CD4 CAR-mediated
infection; and the CD8α TM domain promotes dimerization, which may potentiate
signaling (16, 68, 70). Indeed, improved control over HIV replication by CD4
CARs inversely correlated with the susceptibility of CAR+ CD8 T cells to become
infected, suggesting that HIV infection limits CAR effector activity.
We found that, despite similar levels of specific lysis and stronger cytokine
production in response to Env+ K562 cells, scFv-based CARs could not control
HIV replication as well as CD4-based CARs in vitro, suggesting that CD4 may
recognize HIV Env expressed on the cell surface faster than the scFvs we
examined. Although it is certainly possible that additional scFv CARs could have
superior activity than those described here, we favor the use of T cells
expressing the CD4 CAR due to its extensive clinical safety profile, lack of
immunogenicity, and the dependence HIV shows for using CD4 as an entry
factor (43). While escape from antibody targeting is common in HIV, the reliance
on CD4-mediated entry suggests that escape from CD4 binding will impose
significant, if not lethal, fitness costs. As safety and efficacy of this re-engineered
CAR are demonstrated in HIV-infected individuals, combinatorial approaches
with scFv based CARs may further augment control of HIV replication in the
absence of ART.
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The improved control exhibited by the re-engineered CD4 CAR is
impressive, with at least a 50-fold augmentation in control over HIV replication
(Fig 2-19). Many studies have used similar methods to study the ability of
previous CD4 CAR designs and HIV-specific T cells to limit HIV replication in
vitro and an E:T ratio of 1:1 was generally required to obtain complete control, in
line with what we observed with these constructs (37, 39, 55). The superiority of
CARs compared to a TCR-based approach may be due to antigen-binding
affinity, target cell-binding avidity, T cell activation kinetics, or bypassing the
detrimental effects HIV Nef (2). Overall, the potent control achieved by the reengineered CARs provides optimism for clinical utility and achieving a functional
cure.
We opted to use a NSG hu-T cell mouse model in which human T cells
isolated from human donors would be manufactured in an analogous manner as
a clinical trial. While there are certainly drawbacks to this model, such as GVHD
and the inability to replace CD4 T cells once they are depleted by HIV infection,
this model has been successfully used in preclinical, FDA mandated biotoxicity
and efficacy studies (83, 87) and has mirrored the outcome of several clinical
trials exploring gene therapy approaches to treat HIV infection (82, 83). Our in
vivo results demonstrated that the re-engineered CD4 CARs had potent antiviral
activity, vastly superior to the original CD4-zeta CAR construct. Interestingly, we
saw superior control by the 4-1BB containing CARs both early in infection within
the HIV prevention model and more durable control at late timepoints within the
treatment model, compared to mice treated with CD28 containing CARs. In
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contrast to the mouse data, our in vitro studies show that CD28 costimulation
promoted higher cytokine production and better control over HIV replication,
relative to a CD4 CAR containing 4-1BB costimulation.
One way to reconcile the difference between our in vitro and in vivo finding
is to consider CAR T cell expansion kinetics. We showed in vitro that if the CAR+
CD8 T cells are in sufficient numbers, they can prevent the spread of infection in
all cells; however, if they fall below a critical level, then both the CD4 T cells as
well as the CAR+ CD8 T cells are infected and HIV begins to spread. In our HIV
treatment model, effective early control results in an expansion of more CD4 T
cell targets. If the CAR+ CD8 T cells fail to expand in proportion to the CD4 T
cells or are depleted by HIV, then they may fall below the critical threshold
required to control HIV replication. Differences in the relative expansions of BBz
and 28z CARs in vivo, which may partially be due to better antigen-independent
expansion of BBz, may underlie the differences in HIV control observed between
Fig 2-11 and Fig 2-16. In support of this hypothesis, we observed less 28z CD8
T cell expansion relative to BBz and this correlated to less viral control (Fig 216). Moreover, by the end of the HIV-prevention model, shown in Fig 2-14,
similar control by either CAR resulted when the 28z CARs expanded to a similar
degree as the BBz CARs.
In any case, one would predict using CCR5 ZFNs (88), C34 based fusion
inhibitors (87), or other methods to protect CD4 CAR expressing cells from HIV
infection would further potentiate the therapeutic potential of CD4 CAR T cells.
In addition, the ability to persist in the absence of antigen may be important for a
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functional cure in which durable T cell control may need to last for decades.
Together, our data suggests that CD4 CARs containing the 4-1BB costimulation
domain may be the most effective way to deliver T cell control of HIV replication.
Unfortunately, there is no animal model that faithfully mirrors HIV infection in
humans, and issues of trafficking, immune privilege, and durability are difficult to
fully model in humanized mice. Nonetheless, these data provide the rationale to
re-visit the clinical utility of CD4 CAR in HIV-infected individuals and provide
optimism for CAR T cells to achieving durable control over HIV in the in the
absence of ART.
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Materials and methods

Plasmid construction. pRT43.2 GFP, the backbone of the original clinical trial
vector, was obtained courtesy of Dr. Maribeth Eiden (37, 89) A restriction site
linker was inserted into the PstI and SalI sites, removing the CMV promoter. The
PGK promoter CD4-zeta sequence was amplified from pRRL.PGK.F3 (a gift of
Dr. Tom Dull) with oligos 5’ GTATCGATCACGAGACTAGC and
5’TTAAACCGGTGTCTGGCCTTTGAGTGGTGA and inserted into XhoI and AgeI
sites in the linker within pRT43.2. pTRPE CD4 zeta was created by amplifying
the CD4 extracellular domain was amplified from pRRL.PGK.F3 with primers: 5'
TTAATGGGATCCATGAACCGGGGAGTCCCTTT and 5'
AAGGACTTCCGGATGGCTGCACCGGGGTGGACCATG-3' and inserted into
the BamHI and BspE1 sites in the pTRPE backbone containing the CD8α
extracellular hinge and transmembrane domains and the 4-1BB and CD3 zeta
intracellular costimulatory domains (90). pTRPE lentiviral vectors containing the
CD8α hinge-CD8αTM-CD3ζ or the CD8α hinge-CD28TM-CD28-CD3ζ
intracellular costimulatory domain (ICD) were used as template to PCR amplify
the hinge-TM-and ICD region into the BspE1 and Sal1 sites with primers:5’
GGGACACTCCGGAACCACGACGCCAGCGCCGCG and 5’
GGGACACGTCGACTTAGCGAGGGGGCA. A lentiviral vector that expressed a
B57 restricted TCR capable of recognizing HIV p24Gag epitope KAFSPEVIPMF
(pTRPE B57-KF11) was generated by synthesizing the TCRα and TCRβ gene
sequence (IDT, the TCR sequences were a generous gift of Xu Yu and Bruce
Walker (91)). The TCRα and TCRβ gene sequence was separated by the T2A
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for expression of both TCR genes as previously described (24). VRC01,
3BNC60, PGT128, and PGDM1400 scFv CARs were generated from the
published parental antibody sequences, with a light-linker-heavy chain
configuration (75, 92-95). The linker sequence is: GGSSRSSSSGGGGSGGGG.
Amino acid sequences were codon-optimized (Geneart) and synthesized as
double-stranded DNA fragments (IDT or Geneart), flanked with suitable
restriction sites and cloned into pTRPE plasmids with the BamHI and BspE1
sites. The PG9 scFv was obtained as a generous gift from Dr. Phil Johnson and
cloned into the pTRPE plasmid with the BamHI and BspE1 sites. The amino acid
sequences are found in Fig 2-20.

Virus production and transduction. To generate lentiviral particles, expression
vectors encoding VSV glycoprotein, HIV Gag and Pol, and Rev (pTRP pVSV-G,
pTRP g/p.RRE pTRP.REV) were synthesized by DNA 2.0 and transfected onto
HEK293T cells with pTRPE transfer vectors using the Lipofectamine 2000
transfection reagent (Invitrogen, Life Technologies) as previously described (96).
Transfected HEK293T supernatant was collected at 24 and 48 hour timepoints,
filtered through 0.45 um nylon syringe filters, and concentrated by
ultracentrifugation at 18 hours at 8,500RPM at 4oC. Medium was aspirated and
pellet was resuspended in 1.2ml total volume and stored at -80oC. Murine
retrovirus: 107 293T cells were plated and after 18 hours co-transfected with 20
ug pNGVL3-g/p, 20 ug pMSCV-RD114, and 40 ug pMMTV CD4 zeta transfer
vector also using the Lipofectamine 2000 transfection reagent (Invitrogen, Life
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Technologies). After 24, 48, and 72 hours, supernatants were harvested, filtered
through 0.45 um nylon syringe filters, and frozen at -80C.

Cell culture. Purified CD4 and CD8 T lymphocytes were obtained by University
of Pennsylvania Human Immunology Core/CFAR Immunology Core from deidentified healthy donors. T cells were purified by negative selection using the
RosetteSep Human CD4+ or CD8+ T Cell Enrichment Cocktails according to the
manufacturer’s protocols (StemCell Technologies). T cells were cultured at 1x106
per mL in “complete RPMI 1640:” RPMI 1640 (Life Technologies) supplemented
(ThermoFisher Scientific) wih 10% fetal calf serum (Seradigm), 1% Penn Strep
(Life Technologies), 2 mM GlutaMax (Life Technologies), and 25 mM HEPES
buffer (Life Technologies). T cells were stimulated with anti-CD3/CD28 coated
Dynabeads (Life Technologies) at a 3:1 bead to cell ratio and 100-300 IU/mL of
recombinant human interleukin-2 for 5 days prior to bead removal. 1 day after
stimulation, 200ul of lentivirus supernatant was added to 0.5x10 6 cells. MMLV
vector transduction was performed on days 3 and 5, with 1ml virus supernatant
added to a Retronectin (Takara)-coated 24 well plate and spinoculated according
to the manufacturer’s instructions. Medium was doubled on day 3 and changed
completely on day 5, and then added every other day throughout cell culture, or
as necessary based on cell counts.

In vitro HIV replication control assay and intracellular Gag stain. Two days
after removing the anti-CD3/CD28 beads, CD4 T cells were infected with the
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CCR5-tropic HIV strain Bal, and 24 hours later were co-cultured at varying
effector to target (E:T) ratios with CAR CD8 T cells. Bal viral stocks (280ng/ml
p24) was prepared by harvesting the cell-free supernatant from anti CD3/CD28
activated CD4 T cells and freezing in aliquots. Activated CD4 T cells were
infected by adding approximately 1ml of supernatant per 20 million cells 2-3 days
after removing beads. The following day CD4 and CD8 T cells were co-cultured
at varying E:T ratios and HIV spread was monitored by intracellular p24 Gag with
the KC57 anti-Gag-RD1 antibody (Beckman Coulter) and the Invitrogen Fix and
Perm buffers, according the manufacturers’ instructions, gating on a population
of uninfected cells. To ensure that the same numbers of CAR+ CD8 T cells were
being compared, we diluted out populations with higher transduction efficiencies
by adding in nontransduced T cells until all CAR+ CD8 T cell populations
matched the population with the lowest CAR or TCR transduction efficiency.

Flow cytometry. CD4 CAR surface expression was monitored with mouse anti
human CD8-FITC and anti-human CD4 APC antibodies (BD biosciences). The
scFv CARs were detected with biotinylated F(ab')2 goat anti-human IgG
(Jackson) and Streptavidin-PE (BD biosciences). Cells were visualized on a LSR
II flow cytometer (BD Biosciences) and analyzed using Flowjo software (Tree
Star) as previously described (97). KF11 TCR transduction efficiency was
detected with an antibody to the TCR Vβ17 chain, subtracting the background
Vβ17 signal from the NTD T cells (Fig 2-7 A).

39

In vitro cytotoxicity and cytokine assays. In vitro killing of K562 targets was
tested with a 51Cr-release assay. 5x105 target cells were loaded with 50 mCi of
Na251CrO4 (Perkin Elmer) for 90-120 minutes, washed twice and resuspended in
phenol red-free medium with 5% FBS. NTD, CD4 CAR, or scFv CAR transduced
T cells (two weeks after initial activation) were co-incubated with loaded YU2
Env+ K562 target cells for 4 hours at various E:T ratios, and chromium release
into the supernatant was measured with a MicroBeta2 plate counter (Perkin
Elmer). Intracellular cytokine production was measured after co-culturing
5x105 NTD, CD4 CAR, or scFv CAR transduced CD8 T cells at a 1:1 E:T ratio
with the various target K562 cell populations for 6 hours. Cytokine production
was detected as previously described (98) using rat anti human IL-2 APC (BD
biosciences), mouse anti human MIP-1β PerCP Cy5.5 (BD biosciences), mouse
anti human IFN-γ FITC (BD biosciences), and mouse anti human CD107a PE
(BD biosciences), along with Invitrogen Fix and Perm buffers.

Vector integration qPCR. Genomic DNA was isolated from transduced CD8 T
cells with the iPrep™ Purification Instrument (Thermo fisher scientific) and qPCR
analysis was performed using ABI Taqman technology, with a modified version of
the previously described assay designed to detect the integrated CD4-zeta
sequence in genomic DNA (gDNA) (43). To determine copy number per unit
DNA, a standard curve was generated consisting of 5 to 106 plasmid copies
spiked into 200 ng nontransduced control gDNA. The plasmid copy number in
the standard curve was verified using digital qPCR with the same CD4-z
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primer/probe set, and performed on a QuantStudioTM 3D digital PCR instrument
(Life Technologies). Each data-point was evaluated in triplicate with a positive Ct
value and % CV less than 0.95% for all quantifiable values. To control for the
quantity of interrogated DNA, a parallel amplification reaction was performed
using 10 ng gDNA and a primer/probe set specific for a non-transcribed genomic
sequence upstream of the CDKN1A (p21) gene as previously
described(99). These amplification reactions generated a correction factor to
adjust for calculated versus actual DNA input. Copies of transgene per cell were
calculated according to the formula: [Average copies of transgene(from qPCR)x
gDNA input Correction Factor/Input gDNA(ng)]x 0.0063 ng gDNA/cell.

HIV prevention humanized mouse model. 6 week old NSG (NODscid IL2Rgnull) mice were obtained from The Jackson Laboratory (JAX) and at 7
weeks treated with 30mg/kg Busulfan mixed 1:1 with PBS. 24 hours later mice
were injected via tail vein with 10x106 human lymphocytes in 100ul 0.5% human
serum albumin in PBS, comprised of 8 million CD4 T cells and 2 million CD8 T
cells (NTD, BBz, 28z, or MMLV-CD4z transduced with a 50% transduction
efficiency). Three weeks later mice were tail vein injected with 15ng HIV Bal
mixed 1:1 with PBS. Peripheral blood was obtained by retro-orbital bleeding, and
human CD4 and CAR+ CD8 lymphocyte counts were enumerated using BD lysis
buffer and BD TruCount tubes as previously described (100), staining with
mouse anti human CD45 PerCp Cy5.5 (BD Biosciences), mouse anti human
CD4 BV421 (Biolegend), and mouse anti human CD8α BV711 (Biolegend).
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HIV treatment humanized mouse model. 5 week old NSG (NOD-scid IL2Rgnull)
mice were obtained from The Jackson Laboratory (JAX) and at 6 weeks were
injected with 5 million CD8-depleted human PBMCs, and 12 days later injected
with 1 million HIV Bal-infected (or mock-infected) autologous CD4 T cells that
had been in vitro infected with HIV Bal and cultured with ART for 2 days prior to
freezing. The same day as HIV infection, mice began receiving 200mg/kg daily
intraperitoneal injections of the reverse transcriptase inhibitor nucleotide analog
tenofovir disoproxil fumarate (TDF) for 4 days. On Day 16, 5 million CD8 T cells
were injected (NTD, BBz, or 28z). Peripheral blood was obtained by retro-orbital
bleeding, and human CD4 and CAR+ CD8 lymphocyte counts were enumerated
using BD lysis buffer and BD TruCount tubes as previously described (100),
staining with mouse anti human CD45 PerCp Cy5.5 (BD Biosciences), mouse
anti human CD4 BV421 (Biolegend), and mouse anti human CD8α BV711
(Biolegend).

HIV RNA viral load assay. RNA was extracted from 10-30µl of plasma using
methods as described (101) and reconstituted in a final volume of 15ul. Prior to
extraction, a uniform quantity of Replication Competent Avian Sarcoma (RCAS)
virus spiked into each plasma sample and amplified separately to verify
virus/RNA recovery and absence of PCR inhibition (102). RNA was reverse
transcribed using random hexamers and quantified by Q-PCR using the
LightCycler 480 Probes Master (Roche; Indianapolis, IN) on an ABI 7500FAST
real-time thermocycler using an in vitro transcribed RNA standard. For each
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sample, the Q-RT-PCR reaction was run in duplicate on 5ul RNA; no-reverse
transcriptase reaction and RCAS amplification were run on one well per sample
using 2.5ul RNA. The HIV-1 primer/probe targets the pol gene and detects all
group M clades as described in (101), and RCAS amplification used primer/probe
as described in (102). HIV-1 quantification was normalized to equivalent volumes
of starting plasma.

Culture supernatant p24 detection. Culture supernatant was harvested after 7
days of co-culture and diluted 1:10,000 and analyzed using the commercially
available p24 ELISA assay kit (Perkin-Elmer). Assay protein standards ranged
from 9.4pg/ml to 150pg/ml.

Ultrasensitive p24 detection from mouse plasma. Plasma was collected by
centrifugation of the whole blood and diluted according to a protocol supplied by
Bonnie Howell (Merck & Co, Inc.). The HIV p24 Gag protein was measured
using the p24 single molecule array using the Simoa HD-1 Analyzer (Quanterix)
following the manufacturer’s instructions. Each sample was measured in
duplicate and concentration calculated based on a standard curve. The average
concentration of two replicates for each sample was reported. The accurate
detection range was 0.008pg/ml to 39.5pg/ml.

Statistics. In vitro HIV replication control significance was detected using a 1way ANOVA test, stratifying based on the E:T ratio (p values: ns >0.05, *<0.05,
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**<0.01, ***<0.0001), using the 30:1 E:T ratio for Fig 2-9 A. All E:T ratios are
presented in the figures as a single graph due to space limits. For the mouse
models, non-parametric distributions were determined and Kruskall Wallis
analysis was performed and, if overall comparison showed significant
differences, then Mann Whitney Test was performed for pairwise comparisons
(as samples were not powered for post-hoc analysis of multiple comparisons)
and significance results are reported on each figure (p values: ns >0.05, *<0.05,
**<0.01, ***<0.0001).
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Figures

Figure 2-1. Lentiviral backbone augments CAR expression and control over HIV
replication. (A-D) Primary human CD8 T cells were activated with αCD3/αCD28 coated
beads and were either left (A) nontransduced (NTD), (B) transduced with the original
MMLV-based CD4 CAR, or (C) transduced with the same CAR placed in a HIV-based
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lentiviral vector, both driven by the PGK promoter. After eight days T cells were stained
for CD4 and CD8 by flow cytometry. Median fluorescence intensity (MFI) is indicated on
each graph. (D) Overlying histograms of the data shown in (A-C). (E) Eight days post
activation, qPCR was performed and the number of integrated vector copies per cell was
calculated. (F) Schematic of experimental design to study the control over HIV
replication by T cells expressing HIV-specific CARs. Briefly, following activation with
αCD3/αCD28 coated beads, CD4 T cells were infected with HIV Bal, and 24 hours later
the indicated CD8 T cells were mixed at the indicated effector to target (E:T) ratios.
After 7 days of co-culture, the expression of surface CD4, CD8, and intracellular Gag
was measured by flow cytometry. (G) Intracellular Gag staining on CD8 negative cells,
and (H) Intracellular Gag staining on CD8 positive cells. (I) Summary data for a single
experiment, performed in triplicate, gating on the CD8 negative cells. Error bars indicate
standard error of the mean (SEM). Significance was detected using a 1-way ANOVA
test, stratifying based on the E:T ratio (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001).
This data is representative of three independent experiments. Fig 2-21 shows each of
the 3 independent experiments. (J) Measurement of levels of intracellular Gag in CD8
negative T cells over the time course of an experiment. Each graph represents a
different E:T ratio. Error bars indicate SEM (n=3).
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Figure 2-2. Gating strategy to separate the CD8 T cells from the CD4 T cells. After
setting up our coculture assay, described in the Fig 2-1 legend, HIV replication is
measured by staining for intracellular p24 (Gag). To distinguish between HIV spread
throughout the CD4 T cells and infection of the CD4 CAR+ CD8 T cells, separate gates
are drawn on these two populations. After gating for (A) cell size (FSC versus SSC
plot), (B) CD8 and CD4 are plotted and two gates are drawn: (D) one encompasses all
CD8+ cells and will encompass CD8 single positive nontransduced cells or CD4+ CD8+
double positive, CAR transduced CD8 T cells. The other gate (C) is on CD8 negative
cells, to capture infected cells that have downregulated CD4 as well as CD4 expressing
cells.

47

Figure 2-3. CD4 CAR Transduced CD8 T cells are not infected by cell-free HIV.
Primary human CD8 T cells were activated and either left NTD or transduced with an
optimized CD4 CAR lentiviral expression vector (EF1α promoter, CD8α transmembrane
domain). After eight days the cells were either left uninfected, inoculated with 70ng p24
of HIV Bal by cell-free addition to culture supernatant, or cocultured at varying effector to
target ratios with CD4 T cells that had been previously infected with the same stock of
HIV Bal for 24 hours (20ng p24/1x106 CD4 T cells). After 6 days of culture, cultures
were collected, and the CD8 T cells were gated on and analyzed for intracellular HIV
Gag expression.
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Figure 2-4. EF1α promoter and CD8α transmembrane domains improve CAR
expression and control over HIV. (A) Schematic of the constructs compared in this
figure. (B) CD4 CAR expression 8 days after activation. Median fluorescence intensity
(MFI) is indicated on each graph. (C) Intracellular Gag staining on day 7 of co-culture,
for CD8 negative T cells and (D) for CD8 positive T cells. (E) Summary data for a single
experiment, performed in triplicate, gating on the CD8 negative cells. Error bars indicate
SEM. Significance was detected using a 1-way ANOVA test, stratifying based on the
E:T ratio (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001). This data is representative of
three independent experiments. Fig 2-22 shows each of the 3 independent
experiments. (F) The levels of intracellular Gag in CD8 negative T cells over the time
course of an experiment. Each graph represents a different E:T ratio. Error bars
indicate SEM (n=3).
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Figure 2-5. Supernatant HIV Gag p24 ELISA results correlate with intracellular HIV
Gag p24 staining and flow cytometry. Using the experimental design described in the
Fig 2-1 legend, a coculture assay was performed with the indicated CAR+ CD8 T cell
populations with HIV-infected CD4 T cells. After 7 days of culture, the intracellular p24
Gag was measured by flow cytometry and the culture supernatant from the same wells
was analyzed for p24 Gag by ELISA. Error bars indicate SEM (n=3).
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Figure 2-6. Gag staining in CAR+ CD8 T cells is not an artifact of gating on a small
number of CD8 T cells. Using the experimental design described in the Fig 2-1 legend,
a coculture was performed using CD8 T cells either left NTD or transduced with an
optimized CD4 CAR lentiviral expression vector (EF1α promoter, CD8α transmembrane
domain). After 5 days of co-culture, the intracellular Gag was measured by flow
cytometry, collecting 2 million cells per well to ensure that at the 1:200 dilution, 1x104
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CD8 T cells would be collected. The pattern of infection was compared to that seen in
the same construct used in Fig 2-4 and presented as zebra plots. (A) Shows gating on
CD8 positive cells and (B) shows gating on CD8 negative cells.
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Figure 2-7. KF11 TCR-transduced CD8 T cells recognize Gag peptides presented
by CD4 T cells. (A) Primary human CD8 T cells were obtained from a HLA-B57+
normal donor and activated with αCD3/αCD28 coated beads. Cells were either left
nontransduced (NTD) or transduced to express a HLA-B57 restricted TCR specific for
KAFSPEVIPMF (KF11). KF11 TCR transduction efficiency was detected with an
antibody to the TCR Vβ17 chain, subtracting the background Vβ17 signal from the NTD
T cells. (B) Primary human CD8 T cells from a HLA-B57+ T cell donor were activated
with αCD3/αCD28 coated beads and were either left nontransduced (NTD) or
transduced with a lentiviral vector expression vector for the KF11 TCR, frozen 8 days
post activation, and then thawed 48 hours prior to coculture. Autologous CD4 T cells
were activated with αCD3/αCD28 coated beads and 11 days post activation 10 million
cells were electroporated with 40ug of mRNA encoding the HIV Gag or HIV Pol proteins,
or mock electroporated. After 24 hours, the NTD or KF11 CD8s were cocultured in at a
1:3 E:T ratio for 5 hours and IL-2 and TNFα production was measured.
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Figure 2-8. Re-directed T cells expressing a CD4 CAR are 100-fold more potent
than re-directed T cells specific for B57-KF11. (A) Gag staining on day 6 of coculture for CD8 negative T cells. (B) Summary data for a single experiment performed in
triplicate, gating on the CD8 negative T cells. Error bars indicate SEM. Significance
was detected using a 1-way ANOVA test, stratifying based on the E:T ratio (p values: ns
>0.05, *<0.05, **<0.01, ***<0.0001). This data is representative of three independent
experiments. Fig 2-23 shows each of the 3 independent experiments.
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Figure 2-9. CD4-based CARs control HIV more effectively than broadly neutralizing
antibody-based CARs. (A) Specific lysis of Cr51 labeled K562 target cells expressing
HIV-1 YU2 GP160. Significance was detected using a 1-way ANOVA test on the 30:1
E:T ratio (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001). Data plotted shows the
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average of three independent experiments. Error bars indicate SEM (n=3). (B) Gag
staining on day 6 of co-culture for CD8 negative T cells and (C) the CD8 positive T cells.
The data from the best (PGT128) and one of the worst (PG9) scFv-based CARs are
compared to the CD4 CAR here, but the complete construct comparison is presented in
Supplementary Fig. 6. (D) Summary data for a single experiment performed in
triplicate, gating on the CD8 negative cells. Error bars indicate SEM . Significance was
detected using a 1-way ANOVA test, stratifying based on the E:T ratio (p values: ns
>0.05, *<0.05, **<0.01, ***<0.0001). Data is representative of three independent
experiments. Fig 2-24 shows each of the 3 independent experiments.
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Figure 2-10. ScFv-based HIV specific CARs produce cytokines as well as CD4based CAR do not control HIV replication as well as the CD4 CAR and succumb to
infection. (A) Primary human CD8 T cells were activated either left NTD or transduced
with the indicated CAR vectors. Two weeks post activation, the CD8 T cells were co57

cultured for 6 hours at a 1:1 ratio with K562 cells expressing HIV-1 YU2 GP160, and
intracellular IFNγ and MIP-1β production was measured. Transduction efficiencies were
normalized to 60% prior to co-culture. (B) Using the experimental design summarized
in Fig 1, the HIV-specific CARs were tested for their ability to control HIV-1 replication in
primary human CD4 T cells. NTD, GFP transduced, and CD19-zeta CAR transduced
CD8 T cell treatments were included as controls. After 6 days of co-culture, intracellular
Gag and CD4 staining is shown for CD8 negative T cells. (C) Shows gating on the CD8
positive cells.
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Figure 2-11. ICOS, CD27, and 4-1BB costimulation impair control of HIV replication
in vitro. (A) Gag staining on day 9 of co-culture for CD8 negative T cells. (B) Summary
data for a single experiment performed in triplicate, gated on the CD8 negative T cells.
Error bars indicate SEM. Significance was detected using a 1-way ANOVA test,
stratifying based on the E:T ratio (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001). Data
is representative of three independent experiments. Fig 2-25 shows each of the 3
independent experiments.
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Figure 2-12. HLA-DR expression histogram. K562 cells transduced with vectors
encoding the HLA-DR*0401 α and β chains and single-clone sorted on high expressing
cells, were stained for HLA-DR expression along with K562 control cells that had been
transduced with HLA-A2, and the MHC class II highly expressing Raji B cells.
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Figure 2-13. CD4 CARs respond to Env+ cells and not MHC class II+ cells. (A)
Primary human CD8 T cells were activated with either left NTD or transduced with the
indicated CD4 CARs. Two weeks post activation, the CD8 T cells were co-cultured for 6
hours at a 1:1 ratio with unmodified K562 cells, K562 cells expressing high levels of
HLA-DR, or K562 cells expressing HIV-1 YU2 GP160. Intracellular IFNγ and MIP-1β
expression is shown on the left, and intracellular IL-2 expression and CD107a surface
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mobilization is shown on the right. (B) A co-culture assay was designed to demonstrate
that CD4 CAR+ CD8 T cells do not kill MHC class II-expressing target cells. Briefly, NTD
or CD4 28z CAR transduced CD8 T cells from (A) were co-cultured with K562 cells
expressing both HLA-A2 and GFP as well as K562 expressing both HLA-DR*0401 and
mCherry at a 1:1:1 ratio. Flow cytometry measuring GFP and mCherry expression was
performed immediately after mixing (0 hr) and after 3 days of co-culture (72 hr). C)
Summary data for a single experiment performed in triplicate, measuring the ratio of
HLA-A2/GFP-expressing cells to HLA-DR*0401/mCherry-expressing cells after 24, 48,
and 72 hours of culture. Error bars indicate SEM. Data is representative of three
independent experiments.
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Figure 2-14. Optimized CAR T cells control HIV-1 replication better and expand to
greater levels in vivo than first generation CAR T cells. Cohorts of NSG mice were
infused with 8 million human CD4 T cells and 2 million human CD8 T cells (50% CAR
transduction efficiency). CD8 T cells were either left NTD, transduced with optimized
CD4 CARs containing either 4-1BB or CD28 intracellular costimulatory domains, or the
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clinical trial, MMLV-based CAR, denoted in as NTD, BBz, 28z, and MMLV-CD4z,
respectively. Three weeks post injection, engraftment was measured to determine (A)
baseline peripheral CD4 T cell counts and (C) baseline CAR+ CD8 T cell counts. Two
days later mice were infected with HIV-1 Bal via tail vein injection. 22 days post
infection, (B) endpoint peripheral CD4 T cell counts and (D) CAR+ CD8 T cell counts
were obtained. (E) Seven and (F) eighteen days post infection mice were bled and HIV
RNA copies per μl plasma were determined by qPCR and normalized to CD4 T cell
counts. Mann Whitney Test was used to determine statistical significance (p values: ns
>0.05, *<0.05, **<0.01, ***<0.0001).
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Fig 2-15. HIV treatment model timeline. NSG (NOD-scid IL2Rgnull) mice were injected
with 5 million CD8-depleted human PBMCs, and 12 days later injected with 1 million HIV
Bal-infected (or mock-infected) autologous CD4 T cells. For four days the infected mice
were injected intraperitoneally with 200mg/kg of the reverse transcriptase inhibitor
nucleotide analog tenofovir disoproxil fumarate (TDF) to prevent HIV viremia. Mice were
bled on day 15 to analyze pre-CD8 human cell counts and measure plasma HIV RNA.
On Day 16, 5 million CD8 T cells were injected that were either nontransduced or
transduced with optimized CD4-zeta CARs containing either 4-1BB or CD28 intracellular
costimulatory domains. CD8 T cell transduction efficiencies were normalized to 55%
prior to injection into mice. Mice were bled on day 26 and 34. For logistical reasons the
mice had to be terminated in two groups, with BBz mice terminated on day 37 and the
NTD and 28z terminated on day 40.
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Figure 2-16. CAR T cells containing 4-1BB outperform CAR T cells containing
CD28 in a humanized mouse HIV-treatment model. The experimental timeline and
detailed description is provided in Fig 2-15. CD4 T cell counts are shown (A) 3 days
post ART initiation, prior to CD8 T cell injection (B) 18 days post ART removal and (C) at
the endpoint termination bleeds (21 or 24 days post ART removal). For logistical
reasons the mice had to be terminated in two groups, with BBz mice terminated 21 days
post ART removal and the NTD and 28z terminated 24 days post ART removal. CD8 T
cell counts are shown (D) 10 days post ART removal and CD8 T cell injection (E) 18
days post ART removal and (F) at the endpoint termination bleeds (21 or 24 days post
ART removal). HIV RNA copies per μl plasma were determined by qPCR and
normalized to CD4 T cell counts (G) 10 days post ART removal (H) 18 days post ART
removal and (I) the endpoint bleed. Mann Whitney Test was used to determine
statistical significance (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001).
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Fig 2-17. CD4 and CD8 T cell counts for mock infected NSG mice used in the HIV
treatment model. (A-C) CD4 T cell counts for the mock-infected (HIV-free) components
of the mouse cohorts described in the Fig 8 legend and shown in Fig 7A-C, (A) 3 days
post mock infection, (B) 3 weeks post mock infection, and (C) endpoint. (D-F) CD8 T
cell counts for the mock-infected (HIV-free) components of the mouse cohorts described
in the Fig 8 legend and shown in Fig 7D-F, (D) 2 weeks post mock infection, (E) 3 weeks
post mock infection, and (F) endpoint. Mann Whitney Test was used to determine
statistical significance (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001). (G) Table of the
median CD4 T cell counts at the different timepoints measured for both HIV infected and
mock infected groups.
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Fig 2-18. Measures of HIV p24 Gag protein levels in plasma as detected by
ultrasensitive p24 ELISA. Plasma was isolated from whole blood by centrifugation and
diluted according to a protocol supplied by Bonnie Howell (Merck & Co, Inc.) and the HIV
p24 Gag protein was measured p24 single molecule array using the Simoa HD-1
Analyzer. Values displayed are femtograms p24 per μl plasma normalized to CD4 T cell
counts (A) 10 days post ART removal and (B) the endpoint bleeds, 21 or 24 days post
ART removal. Mann Whitney Test was used to determine statistical significance (p
values: ns >0.05, *<0.05, **<0.01, ***<0.0001).
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Fig 2-19. Summary of improvements made to original clinical trial vector. (A)
Table and schematic depicting the complete list of modifications explored to improve the
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original clinical trial, MMLV-based construct. (B) Using the experimental design
summarized in Fig 1E, primary human CD8 T cells were activated with αCD3/αCD28
coated beads and were either left nontransduced (NTD), transduced with the original
MMLV-based CD4 based CAR driven by the PGK promoter (clinical trial CAR), or
transduced the optimized EF1α-CD8α TM CAR, placed in a HIV-based lentiviral vector.
Transduction efficiencies were normalized to 60% prior to co-culture. After 7 days of coculture with HIV Bal-infected CD4 T cells, the expression of surface CD4 and
intracellular Gag p24 was measured by flow cytometry, gating on CD8 negative T cells.
(C) Shows gating on the CD8 positive cells. (D) Summary data for a single experiment
performed in triplicate, gating on the CD8 negative cells. Error bars indicate SEM (n=3).
Significance was detected using a 1-way ANOVA test, stratifying based on the E:T ratio
(p values: ns >0.05, *<0.05, **<0.01, ***<0.0001). This data is representative of three
independent experiments.
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Optimized CD4 CARs:
CD4 CD28 CD3-zeta sequence:
MNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHW
KNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYIC
EVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQ
GGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQ
VEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKNKEVSVKRVTQDPKL
QMGKKLPLHLTLPQALPQYAGSGNLTLALEAKTGKLHQEVNLVVMRATQLQKN
LTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQ
VLLESNIKVLPTWSTPVQPSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV
HTRGLDFACDFWVLVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMT
PRRPGPTRKHYQPYAPPRDFAAYRSIDRVKFSRSADAPAYQQGQNQLYNELNLG
RREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGE
RRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
Yellow – CD4 EC domain
Turqoise – CD8α hinge
Red – CD28 TM and ICD
Green - CD3 zeta
CD4 4-1BB CD3-zeta sequence:
MNRGVPFRHLLLVLQLALLPAATQGKKVVLGKKGDTVELTCTASQKKSIQFHW
KNSNQIKILGNQGSFLTKGPSKLNDRADSRRSLWDQGNFPLIIKNLKIEDSDTYIC
EVEDQKEEVQLLVFGLTANSDTHLLQGQSLTLTLESPPGSSPSVQCRSPRGKNIQ
GGKTLSVSQLELQDSGTWTCTVLQNQKKVEFKIDIVVLAFQKASSIVYKKEGEQ
VEFSFPLAFTVEKLTGSGELWWQAERASSSKSWITFDLKNKEVSVKRVTQDPKL
QMGKKLPLHLTLPQALPQYAGSGNLTLALEAKTGKLHQEVNLVVMRATQLQKN
LTCEVWGPTSPKLMLSLKLENKEAKVSKREKAVWVLNPEAGMWQCLLSDSGQ
VLLESNIKVLPTWSTPVQPSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAV
HTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCKRGRKKLLYIFKQPFMRPVQT
TQEEDGCSCRFPEEEEGGCELRVKFSRSADAPAYQQGQNQLYNELNLGRREEYD
VLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKG
HDGLYQGLSTATKDTYDALHMQALPPR
Yellow – CD4 EC domain
Turqoise – CD8α hinge
Pink - CD8α TM
Red – 4-1BB ICD
Green - CD3 zeta

Antibody Based CARs
PG9 CD3-zeta sequence:
QRLVESGGGVVQPGSSLRLSCAASGFDFSRQGMHWVRQAPGQGLEWVAFIKYD
GSEKYHADSVWGRLSISRDNSKDTLYLQMNSLRVEDTATYFCVREAGGPDYRN
GYNYYDFYDGYYNYHYMDVWGKGTTVTVSSGGGGSGGGGSGGGGSQSALTQ
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PASVSGSPGQSITISCNGTSNDVGGYESVSWYQQHPGKAPKVVIYDVSKRPSGVS
NRFSGSKSGNTASLTISGLQAEDEGDYYCKSLTSTRRRVFGTGTKLTVLSGTTTP
APRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLL
LSLVITLYCRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPE
MGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTA
TKDTYDALHMQALPPR
PGT128 CD3-zeta sequence:
QSALTQPPSASGSPGQSITISCTGTSNNFVSWYQQHAGKAPKLVIYDVNKRPSGV
PDRFSGSKSGNTASLTVSGLQTDDEAVYYCGSLVGNWDVIFGGGTKLTVLGGSS
RSSSSGGGGSGGGGQPQLQESGPTLVEASETLSLTCAVSGDSTAACNSFWGWVR
QPPGKGLEWVGSLSHCASYWNRGWTYHNPSLKSRLTLALDTPKNLVFLKLNSV
TAADTATYYCARFGGEVLRYTDWPKPAWVDLWGRGTLVTVSSSGTTTPAPRPP
TPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVI
TLYCRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP
RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTY
DALHMQALPPRR
VRC01 CD3-zeta sequence:
EIVLTQSPGTLSLSPGETAIISCRTSQYGSLAWYQQRPGQAPRLVIYSGSTRAAGIP
DRFSGSRWGPDYNLTISNLESGDFGVYYCQQYEFFGQGTKVQVDIKRGGSSRSSS
SGGGGSGGGGQVQLVQSGGQMKKPGESMRISCRASGYEFIDCTLNWIRLAPGKR
PEWMGWLKPRGGAVNYARPLQGRVTMTRDVYSDTAFLELRSLTVDDTAVYFC
TRGKNCDYNWDFEHWGRGTPVIVSSSGTTTPAPRPPTPAPTIASQPLSLRPEACRP
AAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCRVKFSRSADAPAYQ
QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK
MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
3BNC60 CD3-zeta sequence:
DIQMTQSPSSLSARVGDTVTITCQANGYLNWYQQRRGKAPKLLIYDGSKLERGV
PARFSGRRWGQEYNLTINNLQPEDVATYFCQVYEFIVPGTRLDLKGGSSRSSSSG
GGGSGGGGQVHLSQSGAAVTKPGASVRVSCEASGYKISDHFIHWWRQAPGQGL
QWVGWINPKTGQPNNPRQFQGRVSLTRQASWDFDTYSFYMDLKAVRSDDTAIY
FCARQRSDFWDFDVWGSGTQVTVSSSGTTTPAPRPPTPAPTIASQPLSLRPEACRP
AAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCRVKFSRSADAPAYQ
QGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDK
MAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR
PGDM1400 CD3-zeta sequence:
DFVLTQSPHSLSVTPGESASISCKSSHSLIHGDRNNYLAWYVQKPGRSPQLLIYLA
SSRASGVPDRFSGSGSDKDFTLKISRVETEDVGTYYCMQGRESPWTFGQGTKVDI
KGGSSRSSSSGGGGSGGGGQAQLVQSGPEVRKPGTSVKVSCKAPGNTLKTYDLH
WVRSVPGQGLQWMGWISHEGDKKVIVERFKAKVTIDWDRSTNTAYLQLSGLTS
GDTAVYYCAKGSKHRLRDYALYDDDGALNWAVDVDYLSNLEFWGQGTAVTV
SSSGTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPL
AGTCGVLLLSLVITLYCRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDK
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RRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGL
YQGLSTATKDTYDALHMQALPPR
Yellow – ScFv EC domain
Turqoise – CD8α hinge
Pink - CD8α TM
Green - CD3 zeta

Fig 2-20. Annotated Sequence Files for Optimized CD4 CARs and Antibody Based
CARs.

73

Figure 2-21. Triplicate experiments demonstrating that a lentiviral backbone
augments CD4 CAR expression and control over HIV replication. The same
experimental setup (as described in the Fig 2-1 legend) was performed in triplicate and
intracellular HIV Gag is shown at the peaks of HIV replication for three independent
donors, gating on the CD8 negative cells. Error bars indicate SEM (n=3). Significance
was detected using a 1-way ANOVA test, stratifying based on the E:T ratio (p values: ns
>0.05, *<0.05, **<0.01, ***<0.0001).
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Figure 2-22. Triplicate experiments demonstrating that the EF1α promoter and
CD8α transmembrane domains improve CAR expression and control over HIV-1.
The same experimental setup (as described in the Fig 2-4 legend) was performed in
triplicate and intracellular HIV Gag is shown at the peaks of HIV replication for three
independent donors, gating on the CD8 negative cells. Error bars indicate SEM (n=3).
Significance was detected using a 1-way ANOVA test, stratifying based on the E:T ratio
(p values: ns >0.05, *<0.05, **<0.01, ***<0.0001).
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Fig 2-23. Triplicate experiments demonstrating that the CD4 CAR is over 100-fold
more potent than HIV-specific elite controller TCR in vitro. The same experimental
setup (as described in the Fig 2-8 legend) was performed in triplicate and intracellular
HIV Gag is shown at the peaks of HIV replication for three independent donors, gating
on the CD8 negative cells. Error bars indicate SEM (n=3). Significance was detected
using a 1-way ANOVA test, stratifying based on the E:T ratio (p values: ns >0.05,
*<0.05, **<0.01, ***<0.0001).
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Fig 2-24. Triplicate experiments demonstrating that the CD4 CAR controls HIV-1
more effectively than broadly neutralizing antibody based CARs. The same
experimental setup (as described in the Fig 2-9 legend) was performed in triplicate and
intracellular HIV Gag is shown at the peaks of HIV replication for three independent
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donors, gating on the CD8 negative cells. Error bars indicate SEM (n=3). Significance
was detected using a 1-way ANOVA test, stratifying based on the E:T ratio (p values: ns
>0.05, *<0.05, **<0.01, ***<0.0001).

78

Fig 2-25. Triplicate experiments demonstrating that CD28 and 4-1BB
costimulation have opposing effects on the control of HIV-1 replication in vitro.
The same experimental setup (as described in the Fig 2-11 legend) was performed in
79

triplicate and intracellular HIV Gag is shown at the peaks of HIV replication for three
independent donors, gating on the CD8 negative cells. Error bars indicate SEM (n=3).
Significance was detected using a 1-way ANOVA test, stratifying based on the E:T ratio
(p values: ns >0.05, *<0.05, **<0.01, ***<0.0001).
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Table 2-1. Copies of HIV RNA per μl plasma normalized to CD4 T cell counts while
on ART. Mice were injected with 1 million HIV-infected CD4 T cells (See Fig 2-15 for
timeline) and given daily intraperitoneal injections (200mg/kg) of the reverse
transcriptase inhibitor nucleotide analog tenofovir disoproxil fumarate (TDF) for 3 days
and then bled for viral load detection. HIV RNA copies per μl plasma were determined
by qPCR and normalized to CD4 T cell counts.
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CHAPTER 3 – Protecting CAR-Transduced CD8 T Cells from HIV Infection
Parts of this chapter were previously published in:
R. S. Leibman, J. L. Riley, Engineering T Cells to Functionally Cure HIV-1
Infection. Molecular therapy : the journal of the American Society of Gene
Therapy 23, 1149-1159 (2015).

Protecting CD4 CAR+ T lymphocytes from HIV entry

As demonstrated in Chapter 2, expression of the CD4 CAR promotes
HIV-infection of CAR+ CD8 T cells when diluted to low E:T ratios. At such ratios,
the CD8 T cells lose control over HIV replication and the virus is free to spread
among the CD4 T cells in coculture. Therefore, HIV infection appears to limit
CAR T cell functionality, and we suspect that preventing infection of these cells
will further augment their ability to control HIV.
Prior to this dissertation project, much effort has been spent by others on
identifying methods to protect CD4 T cells from HIV infection (to be discussed in
detail below). The selective advantage of HIV-resistant CD4 T cells allows for
expansion in the presence of the virus, due to cytotoxicity to the unprotected CD4
T cells. Preserved key CD4 T-helper cells could then potentially boost CD8 T
cell responses to restore functional CTL control in vivo. Reducing expression of
the CD4 receptor for HIV and the equally required CCR5 or CXCR4 coreceptors
has been explored as a method to prevent infection of host cells. While deleting
CD4 expression is not a viable therapeutic option because of its necessary
functions, strategies that disrupt coreceptor expression or block the virus-
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coreceptor interaction are feasible and have been explored clinically(88, 103,
104).

Fusion inhibitors

Peptides derived from the C-terminus of the GP41 domain of Env (Cpeptides) can be utilized to prevent the fusion of the virion with the host cell
membrane (105). C-peptides interact with the viral GP41 N-terminus to disrupt
six-helix bundle formation, which contains the energy required for fusion.
Membrane-anchored C-peptides block HIV infection in vitro when expressed
from retroviral or lentiviral vectors (106, 107). Perez and colleagues showed a
15-fold reduction in HIV replication when C-peptide transduced primary CD4 T
cells were challenged with the highly virulent BK132 strain of HIV (106).
Resistance mutations to both soluble and membrane bound forms of the Cpeptide-based inhibitor T-20/Enfurvertide did not result in insensitivity to an
optimized C-peptide vector, termed M87o, which included 10 additional amino
acids than T-20 (108). Partial resistance to M87o could be forced after repeated
passaging of HIV on cells expressing sub-optimal expression vectors and was
accompanied by a complex pattern of mutations in both GP120 and GP41
regions of Env (109). M87o-transduced cells were given to 10 patients with drugresistant HIV infection and advanced disease (103). Gene-modified cells were
detected at one year post-infusion in both lymph nodes and peripheral cells, and
CD4 T cell counts increased significantly from baseline.

Four out of seven
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patients who altered their antiretroviral therapy regiments four months into the
trial experienced over a log decline in plasma virus, and the patients who
remained viremic throughout the study had the best persistence of gene modified
cells at one year post infusion. As these therapeutic peptide sequences are
virally derived and overlap with GP41 sequences known to be bound by human
antibodies, they have the potential to trigger immune-mediated deletion.
Therefore, a modified peptide was more recently designed to remove potential
MHC-I and antibody recognition epitopes while retaining antiviral efficacy (110).
Recently, Leslie et al. demonstrated potent inhibition of HIV using a 34
amino acid peptide from the HR2 region of GP41, termed C34, fused to the
sequence of the CXCR4 coreceptor (87). CD4 T cells transduced with a lentiviral
vector to stably express the C34-CXCR4 fusion protein trans-dominantly inhibited
both CCR5- and CXCR4-utilizing strains of HIV. Importantly, viruses that were
resistant to enfuvirtide (a soluble HR2-derived peptide) remained susceptible to
C34-CXCR4, and these transduced cells enriched in humanized mice relative to
untransduced control T cells. Based on these promising results the University of
Pennsylvania is sponsoring a single cohort, open-label phase I trial, currently
open to enrollment (NCT03020524).

Coreceptor editing

The discovery that people who lacked functional CCR5 were both healthy
and resistant to CCR5-tropic strains of HIV prompted researchers to recreate this

84

phenotype with methods designed to disrupt the CCR5 gene loci. A naturally
occurring 32 base pair mutation (Δ32) in the second extracellular loop of CCR5
leads to a translational frameshift and subsequent protein truncation, resulting in
a non-functional receptor not amenable to HIV fusion (111, 112). With an allele
frequency of approximately 10% in Caucasians (although more commonly found
in people of Western European descent), the majority of the population lacks this
non-functional CCR5 allele (113-115). This HIV-resistant phenotype has been
successfully transferred in the only known case of an HIV cure, in which an HIVinfected

patient

with

acute

myeloid

leukemia

received

an

allogeneic

hematopoietic stem cell transplant (HSCT) from a Δ32 homozygous donor and
was determined to be virus-free more than three years after discontinuing
antiretroviral therapy (116, 117). While this case resulted in a successful cure of
HIV, HSCT carries too many risks to be considered as anything but a last-line
treatment option, particularly when the low likelihood of finding a Δ32 HLAmatched donor is considered. In contrast, gene modification of autologous cells
attempts to phenocopy this effect while bypassing the requirement for ablative
conditioning and finding an HLA matched, HIV-resistant donor. The overall goal
is to engineer a population of HIV-resistant cells that could expand in the
presence of replicating virus due to their selective advantage. With enough HIVresistant cells present, patients could theoretically be taken off ART without
detrimental levels of CD4 T cell depletion and progression to AIDS. Over time,
the reservoirs could, in theory, decrease if HIV was unable to spread due to
coreceptor knockout.

85

Many coreceptor knockdown strategies have been tested in primary T
cells or T cell lines including RNAi, antisense RNA, ribozymes, intrabodies, and
intrakines(118-126).

Various degrees of inhibition were observed with these

methods that work by decreasing coreceptor expression at the transcript or
protein levels. However, knocking out the gene loci for the coreceptors ablates
expression at the source. This can be achieved with customizable, gene editing
technologies including zinc finger nucleases (ZFNs), transcription activator-like
effector nucleases (TALENs), and CRISPRs (clustered regularly interspaced
short palindromic repeats).

Coreceptor disruption with zinc finger nucleases

ZFNs are customizable, hybrid restriction enzymes that fuse the FokI
endonuclease to DNA-binding zinc finger domains. Amino acid modifications in
the zinc fingers alter DNA binding specificity, particularly when multiple zinc
fingers are combined and can be selected with phage display (127, 128). ZFNs
are designed in pairs that bind a precise genomic locus in a bidirectional manner
to dimerize the FokI domains with the correct orientation and spacing required for
cleavage (129). This directs the indiscriminate FokI cleavage domain to induce
dsDNA breaks into the desired target sequence, which can lead to gene
knockout by error-prone non-homologous end joining (NHEJ) or gene insertion
by homologous recombination (HR), provided that a homologous substrate is
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introduced along with the ZFNs (130, 131). Utilizing two unique ZFNs that are
active as heterodimers promotes sequence specificity, but also introduces the
possibility that each of the individual ZFNs will homodimerize and cleave offtarget genomic loci. Thus, design modifications should be incorporated to ensure
ZFNs function as obligate heterodimers (104). An attractive aspect of ZFNs is
that they can be transiently added to cells as transcripts, proteins, or nonintegrating vectors to avoid the safety concerns associated with integrating viral
vectors, namely insertional mutagenesis (132). The permanent and heritable
nature of gene disruption allows for long-term therapeutic benefit to be achieved
from short-term ZFN expression.

Perez and colleagues employed an adenoviral (Ad5/35) non-integrating
vector to deliver ZFNs targeting CCR5 loci to primary human CD4 T lymphocytes
(83). The ZFN pair recognized a 24 base pair site within the first transmembrane
domain of CCR5. Sequence analysis of the CCR5 target site revealed a 5 base
pair duplication of the spacer between the ZFN binding sites that occurred in over
30% of the mutated sequences and introduced an early stop codon within the
first transmembrane domain of CCR5. In vitro analysis of primary CD4 T cells
revealed that 33% of CCR5 disrupted cells were homozygous prior to expanding
in an HIV-infected environment. Ultra-deep pyrosequencing was used to detect
off-target cleavage in the 15 potential sites determined by systematic evolution of
ligands by exponential enrichment (SELEX), and a small frequency of off-target
disruption was identified in the CCR2 locus (4% of CCR2 alleles modified
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compared to 36% of CCR5 alleles modified), which is located near CCR5 on the
same chromosome and has a single nucleotide difference in the sequence
targeted by each of the ZFNs. While CCR2 is important for monocyte trafficking,
CCR2-/- mice develop without overt signs of physical or immune impairment, so
it is likely that deletion of CCR2 alleles in a small proportion of lymphocytes
would not lead to noticeable defects. In vivo studies using an immunodeficient
NOD/Shi-scid/IL-2Rγnull (NSG) mouse model of HIV infection resulted in threefold enrichment of ZFN modified cells in infected mice relative to uninfected
controls, one month post infection (83). Fifty days post infection, the majority of
mice had more than 50% of their CCR5 alleles disrupted and a 0.72 log reduction
in plasma viremia. Over time, CD4 counts increased in ZFN treated mice relative
to controls. Yi et al. used an alternative method to deliver CCR5 ZFNs via a nonintegrating lentiviral vector pseudotyped with Envelope from the CXCR4-tropic
HIV strain LAI, in order to selectively transduce CD4 cells within a culture of
unstimulated or PHA stimulated primary PBMCs (133). Reduced viral loads and
preserved CD4 T cells were observed in NSG mice engrafted with transduced
PBMCs from HIV-infected patients with either high or suppressed viral loads.

Although CCR5 can be considered the primary HIV coreceptor and is
required by most viruses during early infection stages, viruses can gain the ability
to utilize CXCR4, and this is associated with increased disease progression (134136). Thus, to fully protect cells from HIV-infection, strategies should aim to
disrupt both CXCR4 and CCR5 expression.

ZFNs targeting the second
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extracellular loop of CXCR4 were employed in a NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(NSG) mouse model of HIV infection and did not appear to impact trafficking, as
CXCR4 disrupted cells were found in equal proportions in the blood and spleen
(137). A caveat is that trafficking in a humanized mouse model does not entirely
reflect the conditions in a human or non-human primate. Protective effects were
not seen when mice were challenged with the X4-tropic HIV BK132 strain, as the
virus mutated in vivo to gain the capacity for CCR5-mediated entry. In another
NSG mouse study using CXCR4-targeted ZFNs, better control over HIV
replication was seen when the X4-tropic HIV strain NL4-3 was used, and this was
accompanied by concomitant increases in CD4 T cell count (138). A subsequent
comparison of dual ZFN-treated primary CD4 T cells established that CCR5 and
CXCR4 could be knocked out in the same cell (139). Deep sequencing analysis
of predicted off-target sites failed to detect modification of these non-target sites,
suggesting that if cross-heterodimerization between CCR5 and CXCR4 targeted
ZFNs occurs it does not result in mutation of additional loci. ZFN treated NSG
mice were then challenged with a combination of HIV Bal and BK132 strains, and
dual-ZFN treated mice had higher CD4 T cell counts than mice given
untransduced cells or cells treated with ZFNs that solely targeted CCR5. Over
time, the proportion of coreceptor-negative cells increased.

Clinical feasibility of CCR5 ZFNs was demonstrated in a study that reliably
generated populations of more than 1010 ZFN treated CD4 T cells from HIVinfected donors, upon stimulation with anti-CD3 and anti-CD28 coated beads
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(140).

Analysis of expanded ZFN transduced cells revealed that these cells

retained similar phenotypes, cytokine production levels, and TCR diversity.
Karyotype analysis detected no chromosomal abnormalities, which might result
from the high proportion of ZFN induced dsDNA breaks. Three clinical trials
using transduced T cells have been performed with these CCR5 ZFNs led by the
University

of

Pennsylvania

(NCT00842634)

and

Sangamo

Biosciences

(NCT01252641 and NCT01044654). The results of NCT00842634, in which 12
patients received ten billion autologous, modified CD4 T lymphocytes (SB-728)
were recently published by Tebas and colleagues (88). The gene modified cells
could be detected in all patients throughout the duration of the study up for 42
months, with a median half-life of 64 weeks, and trafficking to the rectal mucosa
was observed.

Four out of the six patients who

underwent a structured

treatment interruption (STI) completed the 12 week interruption, during which the
viral load decreased by an average of 1.2 logs.

One patient’s viral load

decreased to undetectable levels during STI, and it was later determined that this
patient was heterozygous for the CCR5 Δ32 mutation.

During the STI, the

decline of CCR5 modified cells was significantly less than the unmodified cells.
The rates of HIV DNA decay were found to be 10 times as rapid for SB-728treated patients who maintained suppressed viremia (did not undergo STI)
compared to control aviremic patients who did not receive ZFN-modified cells.

While safety has been demonstrated in these trials, extensive in vitro
characterization identified over a dozen sites (besides CCR2) in human genome
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to which the CCR5 ZFNs had enzymatic activity towards (141, 142) . Notably,
Pattanayak and colleagues found ZFN-mediated cleavage in the promoter of the
BTBD10 gene, and downregulation of this gene has been associated with
malignancy and pancreatic beta-cell apoptosis (141). However, these studies
also demonstrated that decreasing the concentration and DNA binding affinity of
the ZFNs can reduce off-target cleavage activity. Nevertheless, the possibility
exists for the dsDNA breaks to induce transformation, whether through gene
knock out or chromosomal translocations (141, 143).

A similar CCR5 knockout approach was taken with the designer restriction
enzymes known as transcription activator-like effector nucleases (TALENs) (144,
145). TALE DNA binding proteins from the plant pathogens Xanthamonas sp.
can be fused to the FokI endonuclease, as done for ZFNs, to promote sitespecific cleavage (145). While ZFNs recognize three nucleotides per zinc finger
domain (comprised of 30 amino acids), TALENs recognize a single nucleotide
per 34 amino acids.

Side by side comparisons of ZFNs and TALENs were

performed in 293T cells and comparable CCR5 disruption frequencies were
obtained. TALENs had restricted CCR2 cleavage and a two-fold increase in cell
survival compared to ZFNs (144, 146). As off-target effects vary in different cell
types due to structural differences in chromatin, an important safety assessment
of ZFNs and TALENs should include an analogous comparison in primary human
CD4 T cells, the target cell employed in human clinical trials.
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Coreceptor disruption with CRISPR

The CRISPR system was adapted for eukaryotic genome engineering
from bacteria and archaea, in which it functions as a prokaryotic immune system.
Foreign DNA sequences are incorporated as spacers between the CRISPR
repetitive DNA elements and subsequently transcribed and processed into a
CRISPR-RNA (crRNA). The crRNA forms a complex with CRISPR-associated
(Cas) nuclease proteins that digest invading sequences complementary to the
crRNA. For eukaryotic gene editing applications, a type II CRISPR system was
adapted from Streptococcus pyogenes that only requires two components to
function: a guide RNA (gRNA) complementary to the target genomic site and its
associated Cas9 nuclease (147).

Similar to ZFN-mediated cleavage, Cas9

leaves a dsDNA break that can be repaired by NHEJ or HR.

An attractive

feature of this system is that only the gRNA must be altered to adapt it to a
particular genomic site of interest, making it an inexpensive and simple
procedure.

Moreover, multiple gRNAs can be introduced to simultaneously

target multiple loci within the same cell. The only target sequence requirement is
that it be followed by a protospacer adjacent motif (PAM) “NGG” sequence.
Cradick and colleagues designed CCR5-specific gRNAs to assess gene editing
frequencies and off-target effects in 293T cells (148). CCR2 cleavage was seen
at a low frequency in this system, even when two nucleotide mismatches existed.
Additional work has demonstrated that Cas9 tolerates mismatches between the
gRNA and target DNA, depending on the dose of gRNA administered and the
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number and location of mismatches (149, 150).

However, a different study

utilizing CCR5 gRNAs was able to eliminate CCR5 expression in 68% of
transduced TZM.bl cells, without any detectable off-target cleavage at the highly
homologous sites identified by bioinformatics screening (88).

Success of coreceptor editing strategies is contingent on generating
homozygous knockout cells, as demonstrated by the viral load reduction in the
Δ32 heterozygote patient whose cells received CCR5-directed ZFNs (88). Which
method becomes the more useful clinical tool will depend foremost on safety,
followed by efficacy as well as economic and engineering considerations.
Bioinformatic software is readily accessible for researchers to identify off-target
sites where designer endonucleases may cleave, but in vitro and in vivo preclinical testing must follow to verify the results and demonstrate safety(151-154).
Additionally, nickase versions of ZFNs and Cas9 have been designed to promote
HR while avoiding the potentially detrimental effects of NHEJ(155, 156). Using a
pair of Cas9 nickases with two gRNAs that bind close on the chromosome may
facilitate genome editing in a manner more analogous to ZFNs and TALENs and
reduce off-target effects to comparable levels (157).

Unlike the FokI

endonuclease, Cas9 does not require dimerization for functional enzymatic
activity, so fusions of catalytically inactive Cas9 and active FokI have been
designed to impart dimerization requirements on Cas9 while maintaining gRNA
specificity (158, 159).

Analysis of off-target modifications in human genomic
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DNA sites introduced by the FokI-Cas9 chimeras showed 140-fold and 8-fold
reduction relative to WT Cas9 or Cas9 nickases, respectively (159).

Protecting CAR T cells

As described above, the survival benefits afforded by gene editing the
CCR5 HIV coreceptor using ZFNs or by utilizing GP41-based fusion inhibitors
had previously been demonstrated in primary human CD4 T cells (83, 87, 88,
106). Since we showed in Chapter 2 that the CD4 CAR mediates infection into
CD8 T cells expressing this construct and this appears to reduce CAR T cell
functionality and control over HIV, a natural question to ask is whether protected
CAR T cells control HIV better and enrich in the presence of HIV compared to
unprotected CAR T cells.
A handful of groups have recently undertaken efforts to prevent infection
and augment CD4 CAR CD8 T cell functionality by means of coreceptor editing
and fusion inhibitors. Maclean et al. reported greater specific lysis towards Env+
283T cells with rhesus T cells dually transduced to express both an MMLV-based
CD4 CAR and a membrane-bound form of the GP41 derived C46 peptide (160).
Kamata et al. used a CD4-zeta CAR vector that also encoded shRNAs to CCR5
and the LTR sequence and reduced infection of CAR CD8 T cells by cell-free
virus, as determined by culture supernatant p24 Gag (161). They also reported
less cell death in HIV-infected wells compared to mock wells when the shRNAs
were incorporated. Zhen et al. used a similar strategy, combining the CD4-zeta
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CAR with a shRNA that targeted CCR5 and saw a reduction in intracellular Gag
from cell-free virus (62). Lastly, Hale et al. used homology directed insertion to
deliver a PGT145 bNAb-based CAR to the CCR5 locus (162). They saw more
supernatant p24 accumulate when cell free virus was added onto PGT145 CAR
CD8 T cells not treated with the CCR5-directed MegaTAL nuclease. In line with
these efforts, we utilized tools available to our lab which had previously or was
concomitantly being tested to protect CD4 T cells from HIV infection.

We

extended these technologies to determine the impacts of CCR5 ZFN coreceptor
disruption as well as C34-CXCR4 peptide inhibition in CAR T cells.
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Results
Δ32 CD8 T cells delay HIV infection via the CD4 CAR compared to WT CD8
T cells. First, we wanted to determine to what extent the CCR5 coreceptor
contributes to CD4 CAR-mediated infection. To do this, we obtained CD8 T cells
from either a normal, wild-type donor (WT) or a CCR5 Δ32 homozygote donor
and transduced them to express the CD4 28z CAR. We then set up a coculture
with CD4 T cells from the WT donor that could propagate the CCR5-tropic Bal
strain of HIV. Compared to WT CD8 T cells transduced to express the CD4 28z
CAR, the analogous Δ32 CD8 T cells had less intracellular Gag on days 4-6 (Fig
3-1 A). Curiously, after day 6 of infection, the amount of Gag skyrocketed in the
Δ32 CD8 T cells, to levels greater than seen in the WT cells. When looking at
HIV spread throughout the WT CD4 T cell targets, both WT and Δ32 effector
CD8 T cells controlled HIV at the 1:25 and 1:50 E:T ratios, indicated by very low
levels of Gag+ CD4 T cells (Fig 3-1 B). The 1:100 E:T ratio looked similar to the
pattern seen in CD8 T cells, with more control early on by the Δ32 effectors,
which was then lost by day 8 (Fig 3-1 B). As expected, by the 1:200 E:T ratio all
control by the effectors had been diluted out. No clear benefit in enrichment of
the Δ32 CAR CD8 T cells was seen, relative to WT CAR CD8 T cells (Fig 3-1 C).
This is not entirely surprising, given that the Δ32 CAR CD8 T cells succumbed to
HIV infection at later timepoints, and there appeared to be a somewhat inverse
correlation between the amount of intracellular Gag in the CD8 T cells (Fig 3-1
A) and the frequency of CAR CD8 T cells (Fig 3-1 C). Thus it appears that
CCR5 does play a role in CAR-mediated infection, but the extent was difficult to
96

discern in our in vitro coculture. The reason underlying this could have been due
to either CCR5-independent membrane fusion, mediated by CAR CD8 T cells
binding their target cells, or by CCR5 transfer via trogocytosis or microvesicles
(163-165).

Inefficient CCR5 ZFN disruption precludes detecting a benefit against HIV
in vitro. To determine if coreceptor editing promoted better enrichment of CAR
CD8 T cells, we set up an in vitro coculture in which CD8 T cells were either left
unmodified or treated with CCR5 ZFNs prior to CAR transduction. Unfortunately
no benefit to ZFN treatment was seen in this experiment (Fig 3-2 A-C), except
for slightly increased enrichment of 28z and BBz CAR CD8 T cells treated with
ZFNs, compared to their non-ZFN treated counterparts, at the 1:200 E:T ratio. In
fact, the ZFN-treated 28z and zeta CD8 T cells controlled HIV worse than their
untreated counterparts at the 1:100 ratio (Fig 3-2 B and C). It was
retrospectively determined that the CCR5 disruption efficiency in the CD8 T cells
had ranged from 5-7%, likely too small of a protected population to witness a
benefit in a short, in vitro coculture. This poor disruption efficiency was probably
due to a batch of poor quality ZFN RNA, since members of the lab had previously
demonstrated better editing capacity with CCR5 ZFNs, and we proceeded with in
vivo studies using a fresh batch of ZFN RNA.

CCR5-ZFN modified CD4 CAR CD8 T cells are enriched in a humanized
mouse model of HIV infection. After generating CD8 T cells with
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approximately 45% of CCR5 alleles disrupted, we then included 4 additional
cohorts of mice that were CCR5 ZFN treated to the HIV prevention humanized
mouse model described in Fig 2-14. For clarity, only the non-ZFN treated mice
were shown in Chapter 2, though one large experiment was performed. As
mentioned previously, the groups were mice that received wild-type CD4 T cells
and CD8 T cells that were either nontransduced (NTD), transduced with the
optimized lentiviral vector containing either 4-1BB (BBz) or CD28 (28z)
costimulatory domains, or transduced with the clinical trial MMLV-based vector
(MMLV-CD4z). Each of these groups had a ZFN-treated and non-ZFN treated
counterpart, making a total of 8 CD8 T cell conditions. After 3 weeks of HIV
infection, CCR5 disrupted alleles were enriched in mice that were treated with
CD4 CAR T cells, to varying degrees, relative to mock (uninfected) controls, with
the most significant difference seen for the 28z CAR treated group (Fig 3-3 A).
BBz had a high CCR5 disruption in the absence of HIV infection, likely due to the
antigen-independent proliferation effects it imparts on T cells as shown in Fig 217. As expected, the CCR5 disruption was not increased in the presence of HIV
for NTD CD8 T cells, which lacked the CD4 CAR and should not have been
susceptible to HIV infection (Fig 3-3 A). Surprisingly, CCR5 disruption appeared
to be deleterious in the absence of HIV infection. As mentioned, the CD8 T cells
injected into the mice had approximately 45% of their CCR5 alleles disrupted,
and were then diluted 1:5 with CD4 T cells. While we tried to isolate pure
populations of CD8 T cells, our splenocyte preparations were mostly CD4 T cells.
Assuming the 1:5 dilution held true, we would expect on average about 9%
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disruption efficiency in the absence of positive selection, but we saw less than
1% CCR5 disruption in the absence of HIV in all cases except BBz.
We also examined whether rendering CD4 CAR CD8 T cells resistant to
HIV infection enhanced their ability to control HIV-1 infection. In 28z or BBz
mice, which had low viral loads in the absence of ZFN treatment, no further
decrease in viral RNA resulted from ZFN treatment (Fig 3-3 B). On the other
hand, a significant decrease in plasma viral RNA was seen in mice given ZFNtreated MMLV-CD4z T cells, to the point where plasma virus was no longer
significantly higher than mice given the BBz or 28z CARs. As the viral loads
were approximately a log-fold higher in the MMLV-CD4z retrovirus treated mice
without ZFNs compared to BBz or 28z treated mice without ZFNs, it is easier to
detect a significant reduction in viral load in the context of poorly controlled virus
replication resulting from ZFN treatment. Moreover, the short duration of the
experiment could have precluded seeing full benefit of ZFN treatment on CAR T
cells, including a detectable enrichment of transduced CD8 T cells, particularly in
the MMLV-CD4z treated mice in which they yielded the most antiviral benefit.
ZFN treatment did not augment CD4 T cell expansion or increase CAR CD8 T
cell counts, though there was a trend for increased values in the MMLV-CD4z
treated mice (Fig 3-3 C-F). There was also a trend for poorer counts in the 28z
mice that received ZFNs, though these mice had lower CD4 T cell engraftments
at baseline (Fig 3-3 C).
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Lack of antiviral benefit of CCR5 ZFNs in an HIV treatment model. After
promising data with our HIV prevention model, we decided to include CCR5edited cells in our HIV treatment model, described in Fig 2-16, in which BBz or
28z CD8 T cells were previously treated with CCR5 ZFNs. This time we did not
treat any NTD CD8 T cells with CCR5 ZFNs. Prior to injection, the disruption
frequency in the CD8 T cells was around 30%. After approximately 3 weeks post
ART removal, in the HIV-infected mice, we purified CD8 T cells from splenocytes
and analyzed the CCR5 disruption and found that these values remained the
same (Fig 3-4 A). We again saw a high disruption frequency in the mock BBz
mice and a very low disruption frequency in the 28z mock mice, indicative of
either or both an antigen-independent proliferation of the BBz CAR T cells and a
negative selection in the absence of HIV infection against CCR5 disrupted alleles
in the 28z mice (Fig 3-4A). Similar to the results in Fig 3-3, CCR5 ZFN
treatment afforded no benefit in terms of reducing HIV RNA in the mice treated
with these optimized CARs (Fig 3-4 B). However, in the HIV infected mice, ZFN
treatment of CAR CD8 T cells increased both the CD4 and the CD8 T cell
counts, relative to the non-ZFN treated cohorts, though this did not reach
statistical significance (Fig 3-4 C and D, red dots). By the experimental
endpoint, both the CD4 and CD8 T cells were extremely high, likely due to xenoeffects and GVHD. This HIV antigen independent mechanism of proliferation
may underlie the lack of enrichment seen in the CCR5 disrupted alleles in Fig 34 A, and explain the difference between this data and Fig 3-3 A.
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The C34-CXCR4 HIV fusion inhibitor augments control over HIV replication
in vitro by the CD4 zeta CAR. CCR5 surface staining is poorly resolved, so
CCR5 disruption frequency must be determined by examining the proportion of
cells with DNA disruptions. Therefore, we cannot determine what proportion of
cells are both HIV-resistant and CAR-transduced. In contrast, the C34-CXCR4
HIV fusion inhibitor is stably expressed on the cell surface an can be detected via
surface staining, providing a method to determine which cells in culture are both
HIV-resistance and CAR-transduced. We therefore performed a dual
transduction of CD8 T cells so that they would express a CD4 CAR as well as the
C34-CXCR4 inhibitor. C34-CXCR4 expression promoted better enrichment of
CD4 CAR CD8 T cells at the 1:50 and 1:100 E:T ratios (Fig 3-5 A). C34-CXCR4
expression promoted better control over HIV replication at the 1:100 E:T ratio by
the CD4 CAR T cells expressing the CD3-zeta (zeta) costimulatory domain, but
did not augment control by CAR T cells expressing the BBz costimulatory
domains (Fig 3-5 B and D). A similar trend was seen in terms of infection of the
CAR CD8 T cells, with addition of C34-CXCR4 preventing infection of the zeta
CAR at the 1:100 E:T ratio (Fig 3-5 C). The proportion of CD4 CAR+/C34CXCR4+ double positive cells slightly increased over time for the zeta construct,
but decreased over time in the BBz wells that lost control over HIV infection, at
the 1:50 and 1:100 E:T ratios (Fig 3-5 E). These results indicate that C34CXCR4 can augment control over HIV replication and prevent infection of CAR T
cells, but in this case a benefit was not seen for the BBz CAR. We have
previously shown that 4-1BB containing CD4 CARs function poorly in vitro
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relative to CD4 CARs that contain only CD3-zeta (Fig 2-11), and they are more
likely to succumb to HIV infection in vitro, and it is possible that that the C34CXCR4 fusion inhibitor may not be powerful enough to overcome this. Whether
or not this remains true in vivo is unknown.

Bicistronic C34-2A-CAR vector reduces CD4 CAR MFI and result in poorer
control over HIV. Since the dual transduction inevitably results in mixed
populations of cells, some of which are transduced with either vector alone, we
reasoned that it might be beneficial to link CAR expression directly to expression
of the fusion inhibitor. Thus, we generated a bicistronic vector that linked the
CD4 BBz CAR to the upstream C34-X4 fusion inhibitor with the T2A peptide
cleavage sequence. Compared to a single transduction with either C34-CXCR4
or CD4 BBz alone, the 2A vector reduced the median fluorescent intensity (MFI)
of C34 expression by about 75% and CD4 CAR expression by about 60% (Fig
3-6 A). We then compared this 2A fusion construct directly to the dual
transduction in a coculture experiment. We found that the dual transduction
controlled HIV spread throughout the CD4 T cells slightly better (Fig 3-6 B) and
reduced HIV infection in the CAR+ T cells (Fig 3-6 C), particularly at the 1:50 and
1:100 E:T ratios. Interestingly, this benefit over control seemed to be due to the
higher CD4 expression, rather than higher C34 expression, since the dual
transduction (light blue) grouped closer to the unprotected control BBz alone
(red), or a dual transduction with GFP (dark green), seen most clearly at the
1:100 E:T ratio (Fig 3-6 C). However, at the 1:100 and 1:200 E:T ratios, the
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C34-2A-BBz CAR T cells enriched to a greater degree compared to the dual
transduction (Fig 3-6 D). Because you need infection and death of the nonprotected cells in order to see enrichment, it makes sense that we see better
enrichment by the 2A vectors that allow for more HIV replication. Together,
these data indicate that linking the CD4 CAR expression to the fusion inhibitor is
more detrimental than helpful, due to decreased surface expression of the CD4
CAR.
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Discussion

We originally hypothesized that the CD4 CAR clinical trials failed to show
durable reductions in HIV DNA, HIV RNA and infectious virus due to a lack of
cytotoxicity. However, as we performed our first in vitro studies in Chapter 2 we
became aware that the CD4 CAR could be used as a surrogate receptor for HIV
infection. Indeed the original clinical trial construct succumbed to HIV infection at
much lower E:T ratios than our re-engineered CD4 CAR constructs, which were
expressed much higher levels on the cell surface and were superior at controlling
HIV. Nevertheless, it is possible that a combination of augmented cytotoxicity
and protection from HIV infection will be required to achieve durable control by
CAR T cells in HIV patients. We therefore explored two methods to protect our
CD4 CAR T cells, CCR5 disruption by ZFNs and stably expressing the C34CXCR4 fusion inhibitor, with the hypothesis that protected CAR T cells would
control HIV better than unprotected CAR T cells in vitro and in vivo.
Initially we tried to determine if HIV infection of CAR CD8 T cells was
similar to natural cell infection in that it required a coreceptor, such as CCR5.
Using a coculture of allogeneic WT CD4 T cells and CCR5 Δ32 CAR CD8 T cells,
we found that despite an initial delay in HIV infection, the Δ32 cells resulted in
robust HIV infection (Fig 3-1). As mentioned, the CD4 CAR likely facilitated
binding to HIV-infected target cells that expressed CCR5, and membrane fusion
or vesicle transfer may have allowed the Δ32 cells to uptake both CCR5 and HIV
(163-165). It remains confusing why the peak Gag signal was higher in the Δ32
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cells, though it may be explained by the fact that the WT CD8 T cells used in this
experiment were autologous to the donor CD4 T cells. Allogeneic effects or
differences in effector cell health and function between the donors could have
contributed to the higher levels of intracellular Gag in the CAR CD8 T cells and
subsequent loss of control and spread in the CD4 T cells.
We then looked at the benefits afforded by CCR5 disruption in CD4 CAR
T cells in vivo in two humanized mouse models. In the HIV prevention model,
the proportion of CCR5 disrupted alleles increased in the HIV-infected mice given
CD4 CAR CD8 T cells, relative to mock and relative to our predicted infusion
disruption frequency around 9% (Fig 3-3). This would indicate that those cells
were infected by HIV in vivo and had a selective advantage in the presence of
HIV, similar to what had previously been shown for CD4 T cells (83). While we
did not see an increase in the proportion of CCR5 disrupted alleles in the HIV
treatment model, relative to the infusion product, this could be explained by the
extensive proliferation from GVHD by the endpoint of the experiment. By this
timepoint, it is likely that the main cause of T cell proliferation was independent of
HIV-antigen and CAR signaling.
A surprising finding in this experiment was the strong negative selection in
the absence of HIV within our mock control mice for all conditions except BBz. In
retrospect, this was also shown, albeit to a lesser extent, by Perez et al. They
reported a lower frequency of CCR5 disrupted alleles in their mock NOG mice
after a 40 day period, relative to the infusion product, whereas the HIV infected
mice yielded an enriched proportion of CCR5-disrupted alleles (83). Whether
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this is a mouse-specific finding is unknown. A recent clinical trial utilizing CCR5
ZFNs only included HIV-infected patients, so the relative survival of modified
cells in HIV-infected versus uninfected patients is not available (88). In the
future, it would be interesting to specifically label the CCR5 disrupted cells to
analyze their trafficking and phenotypes, but as previously mentioned we cannot
tell by simply staining for CCR5 at the cell surface.
We then went on to utilize a second method of protection on our CAR T
cells in which we could use surface staining to detect which cells were both CARtransduced and HIV resistant. The benefits of the C34-CXCR4 fusion inhibitor
were more readily detectable when using the CD3-zeta containing CAR, relative
to the 4-1BB containing CAR in vitro. Since the benefits of the 4-1BB
costimulatory domain were clearly demonstrated in Fig 2-14 and 2-16, we asked
whether coupling the CAR expression to the C34-CXCR4 expression would
afford better protection and control over HIV in vitro. A negative consequence of
this was decreased surface expression of both the C34-CXCR4 and the CD4
BBz CAR, and the bicistronic vector controlled HIV to a lesser extent than the
dual transduction of two separate vectors expressing either C34-CXCR4 or the
CD4 BBz CAR.
The published reports of protecting CD4 CAR T cells CCR5 shRNA or
surface-expressed GP41 based peptides were notably for cell-free virus
infections, which never occurred in our hands with our optimized CARs. This is
likely because we optimized our CAR for cytolytic potential and showed in
Chapter 2 that greater cytolytic potential reduces the E:T ratio at which CAR
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CD8 T cells become infected. The other, published reports typically used E:T
ratios of 1:1 or higher, whereas our optimized CARs controlled at 1:50 or lower.
Moreover, the reductions they reported were quite small in terms of the overall
benefit, ranging in supernatant p24 or intracellular p24 reductions around 3% or
less. It is also interesting to consider the published mouse models by these
groups. Zhen et al. used the bone marrow-liver-thymus mouse model to
generate CD4-zeta/CCR5 shRNA expressing hematopoietic stem cells; however
they did not include a treatment group expressing solely the CD4-zeta CAR and
without the CCR5 shRNA, analogous to our non-ZFN treated, CAR CD8 T cell
injected mice (62). Moreover, the follow-up Hale et al. study that included an
NSG mouse model inserted a CD19-scFv CAR into the CCR5 locus with
MegaTALs, and looked at tumor reduction rather than HIV-specific CAR function
(166). Thus, data demonstrating a clear in vivo benefit from protecting CAR T
cells is lacking, despite initial reports of modest in vitro efficacy by these groups.
Overall, we conclude that a high level of CD4 CAR expression is critical
for controlling HIV replication and also preventing infection of the CAR T cells
themselves. While higher C34 expression logically seems like it would be critical
for sufficient protection, our in vitro data emphasizes the importance of high CD4
CAR expression over high C34 expression. However, these short term cocultures may not represent the impact of protection in an in vivo infection in which
CAR T cells may succumb to dysfunction and exhaustion if not protected. Direct
in vivo comparisons, not only of unprotected versus protected CAR T cells but
also of the ZFN and the C34-CXCR4 protection methods, will be critical to
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discern the best method for promoting long-term control. Moreover it is possible
that a combination of CCR5 disruption and co-expression of the CD4 CAR linked
to the C34-CXCR4 fusion inhibitor may be the optimal solution.
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Materials and methods

Virus production and transduction. To generate lentiviral particles, expression
vectors encoding VSV glycoprotein, HIV Gag and Pol, and Rev (pTRP pVSV-G,
pTRP g/p.RRE pTRP.REV) were synthesized by DNA 2.0 and transfected onto
HEK293T cells with pTRPE transfer vectors using the Lipofectamine 2000
transfection reagent (Invitrogen, Life Technologies) as previously described (96).
Transfected HEK293T supernatant was collected at 24 and 48 hour timepoints,
filtered through 0.45 um nylon syringe filters, and concentrated by
ultracentrifugation at 18 hours at 8,500RPM at 4oC. Medium was aspirated and
pellet was resuspended in 1.2ml total volume and stored at -80oC.

Cell culture. Purified CD4 and CD8 T lymphocytes were obtained by University
of Pennsylvania Human Immunology Core/CFAR Immunology Core from deidentified healthy donors. T cells were purified by negative selection using the
RosetteSep Human CD4+ or CD8+ T Cell Enrichment Cocktails according to the
manufacturer’s protocols (StemCell Technologies). T cells were cultured at 1x106
per mL in “complete RPMI 1640:” RPMI 1640 (Life Technologies) supplemented
(ThermoFisher Scientific) wih 10% fetal calf serum (Seradigm), 1% Penn Strep
(Life Technologies), 2 mM GlutaMax (Life Technologies), and 25 mM HEPES
buffer (Life Technologies). T cells were stimulated with anti-CD3/CD28 coated
Dynabeads (Life Technologies) at a 3:1 bead to cell ratio and 100-300 IU/mL of
recombinant human interleukin-2 for 5 days prior to bead removal. 1 day after
stimulation, 200ul of lentivirus supernatant was added to 0.5x10 6 cells. MMLV
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vector transduction was performed on days 3 and 5, with 1ml virus supernatant
added to a Retronectin (Takara)-coated 24 well plate and spinoculated according
to the manufacturer’s instructions. Medium was doubled on day 3 and changed
completely on day 5, and then added every other day throughout cell culture, or
as necessary based on cell counts.

CCR5 ZFN Disruption. Previously described CCR5 specific ZFNs (88) were
cloned into a RNA expression vector (167). The mMessage mMachine T7
Transcription Kit (Ambion, Thermo Fisher Scientific) was utilized to generate
capped, in vitro transcribed RNA, which was subsequently purified with the
RNeasy Mini Kit (Qiagen) and eluted in RNase-free water at 1 mg/ml. Normal
donor CD8 T cells were washed three times with OPTI-MEM medium and resuspended at a final concentration of 1x10 8/ml prior to electroporation. 10E6 T
cells in 0.1ml were mixed with 30μg of RNA encoding for each ZFN,
electroporated in a 2 mm cuvette (Harvard Apparatus BTX) using an ECM830
Electro Square Wave Porator (Harvard Apparatus BTX), and incubated at 30 oC
for 48 hours prior to activation with αCD3/αCD28 coated Dynabeads (Life
Technologies).
To measure efficiency of genome modification by CCR5 ZFNs, genomic
DNA was purified from T cells and used to prepare samples for Illumina deep
sequencing as described before (168). Briefly, the CCR5 target region was
amplified and MiSeq adaptor was added using a nested PCR method with the
following 2 CCR5-specific primer pairs. CCR5 Out-Out1 primers:
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CTGTGCTTCAAGGTCCTTGTCTGC and CTCTGTCTCCTTCTACAGCCAAGC;
CCR5 MiSeq adaptor primers:
ACACGACGCTCTTCCGATCTNNNNNGCCAGGTTGAGCAGGTAGATG and
GACGTGTGCTCTTCCGATCTGCTCTACTCACTGGTGTTCATCTTT. Sequence
barcodes were then added in the subsequent PCR reaction using the barcode
primer pairs. For analysis of gene modification levels, a custom-written computer
script was used to merge paired-end 150bp sequences, and adapter trimmed via
SeqPrep (John St. John, https://github.com/jstjohn/SeqPrep, unpublished).
Reads were aligned to the wild-type template sequence. Merged reads were
filtered using the following criteria: the 5’ and 3’ ends (23bp) must match the
expected amplicon exactly, the read must not map to a different locus in the
target genome as determined by Bowtie2 (169) with default settings, and
deletions must be <70% of the amplicon size or <70bp long. Indel events in
aligned sequences were defined as described previously (170), with the
exceptions that indels of 1bp in length were also considered true indels to avoid
undercounting real events, and true indels must include deletions occurring
within the sequence spanning between the penultimate bases (adjacent to the
gap) of the binding site for each partner ZFN.

In vitro HIV replication control assay and intracellular Gag stain. Two days
after removing the anti-CD3/CD28 beads, CD4 T cells were infected with the
CCR5-tropic HIV strain Bal, and 24 hours later were co-cultured at varying
effector to target (E:T) ratios with CAR CD8 T cells. Bal viral stocks (280ng/ml
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p24) was prepared by harvesting the cell-free supernatant from anti CD3/CD28
activated CD4 T cells and freezing in aliquots. Activated CD4 T cells were
infected by adding approximately 1ml of supernatant per 20 million cells 2-3 days
after removing beads. The following day CD4 and CD8 T cells were co-cultured
at varying E:T ratios and HIV spread was monitored by intracellular p24 Gag with
the KC57 anti-Gag-RD1 antibody (Beckman Coulter) and the Invitrogen Fix and
Perm buffers, according the manufacturers’ instructions, gating on a population
of uninfected cells. To ensure that the same numbers of CAR CD8 T cells were
being compared, we diluted out populations with higher transduction efficiencies
by adding in nontransduced T cells until all CAR CD8 T cell populations matched
the population with the lowest CAR or TCR transduction efficiency.

Flow cytometry. CD4 CAR surface expression was monitored with mouse anti
human CD8-FITC and anti-human CD4 APC antibodies (BD biosciences). C34
staining was performed using a monoclonal antibody, generated at
GreenMountain Antibodies (Burlington, VT) as previously described (87).
FluorescenceCells were visualized on a LSR II flow cytometer (BD Biosciences)
and analyzed using Flowjo software (Tree Star).

HIV prevention humanized mouse model. 6 week old NSG (NODscid IL2Rgnull) mice were obtained from The Jackson Laboratory (JAX) and at 7
weeks treated with 30mg/kg Busulfan mixed 1:1 with PBS. 24 hours later mice
were injected via tail vein with 10x106 human lymphocytes in 100ul 0.5% human
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serum albumin in PBS, comprised of 8 million CD4 T cells and 2 million CD8 T
cells (NTD, BBz, 28z, or MMLV-CD4z transduced with a 50% transduction
efficiency, either modified with CCR5 ZFNs or left unmodified) Three weeks later
mice were tail vein injected with 15ng HIV Bal mixed 1:1 with PBS. Peripheral
blood was obtained by retro-orbital bleeding, and human CD4 T cell and CAR
CD8 T cell counts were enumerated using BD lysis buffer and BD TruCount
tubes as previously described (100), staining with mouse anti human CD45
PerCp Cy5.5 (BD Biosciences), mouse anti human CD4 BV421 (Biolegend), and
mouse anti human CD8α BV711 (Biolegend).

HIV treatment humanized mouse model. 5 week old NSG (NOD-scid IL2Rgnull)
mice were obtained from The Jackson Laboratory (JAX) and at 6 weeks were
injected with 5 million CD8-depleted human PBMCs, and 12 days later injected
with 1 million HIV Bal-infected (or mock-infected) autologous CD4 T cells that
had been in vitro infected with HIV Bal and cultured with ART for 2 days prior to
freezing. The same day as HIV infection, mice began receiving 200mg/kg daily
intraperitoneal injections of the reverse transcriptase inhibitor nucleotide analog
tenofovir disoproxil fumarate (TDF) for 4 days. On Day 16, 5 million CD8 T cells
were injected (NTD, BBz, or 28z) with a 50% transduction efficiency, either pretreated with CCR5 ZFNs or left ZFN untreated. Peripheral blood was obtained
by retro-orbital bleeding, and human CD4 T cell and CAR CD8 T cell counts were
enumerated using BD lysis buffer and BD TruCount tubes as previously
described (100), staining with mouse anti human CD45 PerCp Cy5.5 (BD
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Biosciences), mouse anti human CD4 BV421 (Biolegend), and mouse anti
human CD8α BV711 (Biolegend).
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Figures

Figure 3-1. Δ32 CD8 T cells delay HIV infection via the CD4 CAR compared to WT
CD8 T cells. CD4 T cells were obtained from a normal, CCR5 wild-type (WT) donor,
infected with HIV Bal, and cocultured with autologous CD8 T cells or allogeneic CD8 T
cells from a CCR5 Δ32 homozygote, both of which had been transduced to express the
CD4 28z CAR. (A) Shows the proportion of CD8 T cells that stained positively for
intracellular HIV Gag. (B) Shows the proportion of CD8 negative T cells that stained
positively for intracellular HIV Gag. (C) Shows the proportions of CD4 CAR CD8 T cells
over time in the cultures. Samples were done in triplicate and the average values are
plotted at each timepoint.
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Figure 3-2. Inefficient CCR5 ZFN disruption precludes detecting a benefit against
HIV in vitro. Normal donor CD8 T cells were electroporated with CCR5 ZFN RNA and
subsequently activated with αCD3/CD28 beads and transduced to express CD4 CARs
with the BBz, 28z, or zeta costimulatory domains. These CD8 T cells were then
cocultured with autologous, HIV Bal-infected CD4 T cells and monitored for intracellular
Gag and CAR expression over time. (A) Shows the frequencies of CD4 CAR CD8 T
cells over time in the cultures. (B) Shows the proportion of CD8 negative T cells that
stained positively for intracellular HIV Gag. (C) Shows the proportion of gating on the
CD8 T cells that stained positively for intracellular HIV Gag. Samples were done in
triplicate and the average values are plotted at each timepoint.
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Figure 3-3. CCR5-ZFN modified CD4 CAR CD8 T cells are enriched in a humanized
mouse model of HIV infection. Cohorts of NSG mice were infused with 8 million
human CD4 T cells and 2 million human CD8 T cells (50% CAR transduction efficiency).
CD8 T cells were either left mock electroporated or electroporated with CCR5 ZFN RNA,
and subsequently left nontransduced (NTD) or transduced with optimized CD4 CARs
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containing either 4-1BB or CD28 intracellular costimulatory domains, or the clinical trial,
MMLV-based CAR, denoted in as NTD, BBz, 28z, and MMLV-CD4z, respectively.
Three weeks post injection, mice were infected with HIV. (A) 22 days post infection mice
were euthanized and CCR5 disruption PCR analysis was performed on CD8 T cells
purified from splenocytes. (B) 18 days post infection mice were bleed and HIV RNA
copies per μl plasma were determined by qPCR and normalized to CD4 T cell counts.
(C) Baseline CD4 T cell counts after 3 weeks of T cell engraftment (D) Endpoint CD4 T
cell counts after 22 weeks of HIV infection (E) Baseline CAR CD8 T cell counts after 3
weeks of T cell engraftment (F) Endpoint CAR CD8 T cell counts after 22 weeks of HIV
infection. Mann Whitney Test was used to determine statistical significance (p values:
ns >0.05, *<0.05, **<0.01, ***<0.0001).
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Figure 3-4. Lack of antiviral benefit of CCR5 ZFNs in an HIV treatment model. The
experimental timeline and detailed description is provided in Fig 2-15. For logistical
reasons the mice had to be terminated in two groups, with BBz mice terminated 21 days
post ART removal and the NTD and 28z terminated 24 days post ART removal. (A)
CCR5 disruption PCR analysis performed on CD8 T cells purified from splenocytes. (B)
At the endpoint termination bleeds HIV RNA copies per μl plasma were determined by
qPCR and normalized to CD4 T cell counts. (C) Endpoint termination CD4 T cell counts
and (D) Endpoint termination CD8 T cell counts. Mann Whitney Test was used to
determine statistical significance (p values: ns >0.05, *<0.05, **<0.01, ***<0.0001).
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Figure 3-5. The C34-CXCR4 HIV fusion inhibitor augments control over HIV
replication in vitro by the CD4 zeta CAR. Coculture results using normal donor, Balinfected CD4 T cells and autologous CD8 T cells transduced to express either a CD4
CAR alone or dually transduced to express both a CD4 CAR and the C34-CXCR4 HIV
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fusion inhibitor. (A) Shows the proportions of CD4 CAR CD8 T cells over time in the
cultures. (B) Shows the proportion of CD8 negative T cells that stained positively for
intracellular HIV Gag at the 1:50 and 1:100 E:T ratios. (C) Shows the proportion of CD8
T cells that stained positively for intracellular HIV Gag. Samples were done in singlet
and these values are plotted at each timepoint.
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Figure 3-6. Bicistronic C34-2A-CAR vector reduces CD4 CAR MFI and result in
poorer control over HIV. Primary human CD4 and CD8 T cells were activated with
αCD3/αCD28 coated beads and were transduced to express either monocistronic vector
(C34-CXCR4 or CD4 BBz), the bicistronic vector C34-CXCR4-2A-CD4-BBz, or dually
transduced with both the C34-CXCR4 and CD4 BBz vectors. (A) After eight days T cells
were stained for CAR and C34 surface expression by flow cytometry and the histograms
of the CD8 T cells are depicted. Median fluorescence intensity (MFI) for each condition
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is indicated in the table to the right. The CAR transduced CD4 and CD8 effector cells
were then mixed 1:1 and added to a coculture with autologous HIV Bal infected CD4 T
cells. (B) Shows the proportion of CAR negative (CD4) T cells that stained positively for
intracellular HIV Gag. (C) Shows the proportion of CAR (CD4 high) T cells that stained
positively for intracellular HIV Gag. (D) Shows the proportion of CAR (CD4 high) T cells
over time. Samples were done in duplicate and the average values are plotted at each
timepoint.
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CHAPTER 4 – Modeling CAR T cell killing of the latent reservoir

Introduction

While ART is capable of suppressing HIV replication in the blood, it cannot
target the quiescent HIV reservoir, the source of virus reemergence after ART
cessation (171). Thus, the ultimate goal of HIV cure research is to maintain
suppression of HIV in the absence of ART, whether by achieving effective
immune control (a “functional cure”) or by purging the latent reservoir entirely
(“sterilizing cure”) (172). Methods of purging the latent reservoir have ranged
from attempts to excise viral genomes using CRISPR to attempts to induce HIV
expression using latency reversing agents (LRAs) to promote apoptosis by virusinduced cytopathic effects (CPE) or cytotoxic immune recognition (49, 173, 174).
However, virus rebound can occur even in patients with extremely small
reservoirs, so it is unlikely that LRAs will induce sufficient CPE to remove all
latently-infected cells. Thus, it is conceivable that immune control mechanisms
will be required for long-term suppression of HIV replication (175-177).
On one hand, a functional cure could be achieved by complete
suppression of virus production, such as permanent silencing of proviruses.
Attempts to silence proviruses have been made with ZFNs to incorporate KRAB
DNA repression domains or to induce repressive chromatin marks (178-180). On
the other hand, a functional cure could be achieved by augmenting hostmediated immune responses, and much effort has been spent trying to
understand the determinants of immune control. For example, elite controllers
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suppress HIV to very low or undetectable levels in the absence of ART and never
require therapy, whereas post-treatment controllers initiate ART early after
infection and spontaneously control their virus after ART-removal at a frequency
higher than predicted in the general HIV patient population (181, 182). An active
area of HIV cure research either attempts to enhance T cell responses to mimic
elite controllers or attempts to augment additional immune control mechanisms.
These immune-modulating strategies are widely diverse and include: therapeutic
vaccination, adoptive cell transfer with dendritic cells or T cells, infusion of
antibodies that neutralize HIV and/or recruit cellular effector mechanisms,
infusion of antibodies to promote immune cell killing (such as PD-1 blocking
antibodies, IFNα administration, among others (49, 183-187).
Yet accurately modeling the in vivo efficacy of these developmental
therapies in HIV patients is highly challenging. An area of wide debate in the
latency field is how best to model and how to measure the reservoir, either using
in vitro models or animal models of latency (188, 189). The pool of latently
infected cell in patients is established early and maintained in resting cells over
months or years by homeostatic and antigen-induced proliferation, accompanied
by complex chromatin modifications in heterogeneous cell compartments located
in different tissue compartments (190, 191). This is difficult to recapitulate in
short term cell culture models, which may use spinoculation to infect cells in vitro
or result to artificial means to extend cell survival such as transduction with Bcl-2
or addition of cytokines to promote infection of resting cells (188). Other models
have used ART patient cells, in attempts to model therapeutic treatment of
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natural, patient reservoirs (192, 193). Not only is this complicated by the rare
frequency of latent cells in vivo, requiring collection of large numbers of PBMCs
for analysis, but most proviruses are replication incompetent, so it is difficult to
accurately estimate the true, infectious HIV reservoir (191, 194).
Many classes of LRAs have been developed, though none have been
explored as extensively as histone deacetylace inhibitors (HDACi), many of
which have been employed in clinical trials after successful in vitro data (195).
We tested three of these agents which had made it to clinical testing phases due
to their HIV-activation effects and lack of overt toxicity: SAHA (Vorinostat),
Romidepsin, and Panobinostat. However, both in our hands an others, HDACi’s
have failed to live up to their initial promise (to be discussed below). One
challenge that has been met with the LRA approach, regardless of the class of
drug used, is that cells are not uniformly activated (even with ex vivo drug
treatment) to produce virus, and multiple stimulations can induce sequential
bursts of virus production, so it is difficult to gauge the true proportion of cells
harboring replication-competent, inducible proviruses (194).
The ultimate goal of this dissertation is to create CAR T cells that are
capable of suppressing HIV in patients after ART removal, enabling a functional
cure. This could be achieved by long-term cell CAR T survival combined with
rapid killing kinetics that could eliminate latently-infected cells prior to virion
release, which has been shown for T cells from HIV viremic controllers (196).
The data presented in Chapters 2 and 3 focused on enhancing CAR T cell
cytotoxicity and function, using models that employed activated, normal human
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donor T cells, infected with a lab grown strain of HIV. This allowed us to achieve
maximal production of virus and a high proportion of Gag+, HIV-infected CD4 T
cells, which allowed us to easily detect differences in HIV control and HIV spread
between wells with different CAR conditions being compared. However, the
infected target cells in HIV patients will likely be a relatively rare population of
resting cells, producing much fewer virions than those utilized in our in vitro
activated cell assays. Moreover, virus evolution over months or years in a
patient may result in a quasispecies unlike our Bal infections (197). Therefore,
we attempted to model the latent reservoir in order to determine if CAR CD8 T
cells, including those from HIV donors, could kill resting CD4 T cells from patients
on ART. We furthermore included various HDACi LRAs in these models to
determine if they enhanced HIV expression and CAR CD8 T cell killing.
.
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Results:

CD4 CAR CD8 T cells reduce HIV Gag in a spinoculation model of HIV
latency. To determine if CAR CD8 T cells are capable of targeting resting CD4
T cells producing low levels of HIV, we collaborated with the laboratory of Dr.
Una O’Doherty, which had previously established a spinoculation model of HIV
latency (198). In this model, HIV supernatants are centrifuged along with resting
normal donor CD4 T cells, and following this spinoculation process the CD4 T
cells are washed and then cultured alone or cocultured with CD8 T cells that
were either left nontransfected (NTD) or transfected with CD4 CAR RNA. In
addition, LRAs can be added such as the HDACi SAHA, which was included in
the model shown in Fig 4-1. After a 48 hour coculture, the wells were collected
and stained for intracellular Gag and measured by flow cytometry. HIV infected
cells cultured alone were approximately 4% Gag+ (Fig 4-1B), whereas those
cultured in the presence of SAHA actually had less Gag (2.5%, Fig 4-1C).
Culturing in non-transfected (NTD) control CD8 T cells increased Gag relative to
the CD4s with SAHA (Fig 4-1D). In contrast, culturing CD4 CAR transfected
CD8 T cells, either in vehicle control or in the presence of SAHA reduced HIV
down to approximately 1-1.5% (Fig 4-1E and F). Of note, a mutant version of
CD4 (which was comprised of domain 1 of CD4 and mutated to bind Env with
higher affinity) was utilized as the HIV-binding domain of the CAR in this
experiment (199). These preliminary results suggested CD4 CAR T cells could
target resting cells expressing lower levels of HIV than our activated CD4 T cell
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system shown in Chapters 2 and 3. While this model augmented the proportion
of “latent” HIV-infected cells and allowed us to detect CAR T cell killing, we
wanted to better represent treatment of patients’ viral reservoirs, and so future
experiments utilized CD4 T cells from patients on ART

Intracellular Gag staining is not sensitive enough to detect CAR T cell
reduction of HIV in ART patient CD4 T cells. We next performed coculture
experiments with CAR-transduced CD8 T cells mixed in with CD4 T cells from
patients on ART, in the presence LRAs to augment virus production. As the
proportion of latently infected cells in ART patients is typically 1 in 104 or 105
cells, we reasoned that we would need to augment the production of HIV in order
to detect a reduction in the proportion of HIV-infected cells treated with CAR CD8
T cells (200). We therefore, used a variety of LRAs including the HDACis SAHA
and Romidepsin, a protein kinase C agonist termed C7A, and the BET protein
inhibitor JQ1 and collected large numbers of CD4 T cells. As expected, the
baseline proportion of intracellular Gag+ cells identified by flow cytometry was
extremely low, at less than 0.1% (Fig 4-2A). Unfortunately, we were unable to
see consistent increases in the proportion of Gag+ cells upon treatment with the
various LRAs (Fig 4-2A, and data not shown). Moreover, treatment with
αCD3/αCD28 coated beads only increased the proportion of Gag+ cells by a
small fraction (i.e. 0.1% of cells to 0.5%, Fig 4-2A), despite evidence of cellular
activation upon αCD3/αCD28 stimulation, as evidenced by an upregulation of
CD69 surface expression (Fig 4-2B). In contrast to our predictions, coculturing

129

CD8 T cells, regardless of CAR expression, slightly increased activation of the
CD4 T cells and the proportion of Gag+ cells (Fig 4-2). Based on these
experiments, we concluded that we would need to collect an unfeasible number
of cells per condition to get a reliable proportion of Gag+ cells, and decided to
utilize other methods to measure the HIV reservoir besides intracellular Gag
staining and flow cytometry.

Integrated HIV DNA is more readily detected in ART patient cells. We
returned to our collaboration with the O’Doherty lab to utilize their established
assay to measure integrated HIV DNA in cells from ART patients (201, 202). We
set up a 24 hour coculture similar to that described in Fig 4-2, culturing ART
patient CD4 T cells alone, or in the presence of unmodified control CD8 T cells
(NTD), lentivirally transduced CD4 CAR CD8 T cells (preactivated), or RNAtransfected, resting CD4 CAR CD8 T cells. We utilized Romidepsin as the LRA
in this experiment and also looked at the effects in the presence of ART, which
would prevent viral spread in the event of latent cell reactivation. After a 24 hour
coculture, the wells were analyzed for the proportion of HIV DNA per million cells.
There was a reduction of integrated HIV DNA in conditions given LRAs with
either CAR CD8 T cell condition, relative to NTD control CD8 T cells or CD4 T
cells cultured alone (Fig 4-3, green and turquoise bars). However, why these
values would be higher for the NTD coculture wells relative to CD4 only T cells
remains perplexing, though we did not measure cellular activation in these
experiments, and it is possible the CD8 T cell coculture wells were more
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activated and stimulatory to HIV in general; though in that case we could expect
all NTD CD8 wells to have higher HIV DNA levels, including –LRA+ART
condition (Fig 4-3, purple bars). Around the same time, new technology was
being developed to measure ultrasensitive p24 values. We validated this
technology in our HIV-treatment mouse model shown in Fig 2-16 and decided to
employ this assay to measure HIV in reservoir cells in the hopes that this high
throughput assay could provide more robust data.

Ultrasensitive p24 detection can be used to measure CAR T cell killing of
ART patient cells. The SIMOA HD-1 analyzer is a high throughput assay that
uses ultrasensitive ELISA technology to detect HIV p24 Gag protein. Measuring
p24 Gag protein production may better estimate the size of the infectious
reservoir compared to a PCR that amplifies only a small portion of the HIV
genome, such as the integrated DNA assay we were using (194). To our
surprise, we found out that this assay is sensitive enough to detect leftover p24
from the lentivirus packaging plasmids (data not shown). Therefore, we
employed RNA transfected CD8 T cells in coculture assays to avoid false
positive HIV detection of the lentiviral vector. Moving forward, we chose to
employ the LRA panobinostat in place of romidepsin, since it was effective in
published latency models and was less toxic to activated lymphocytes in our
hands as well as others (203, 204). We also compared the effects on p24
protein levels by resting CD8 T cells versus those that had been previously
activated with αCD3/αCD28 coated beads, prior to electroporation of CD4 CAR
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RNA. After a 72 hour coculture of normal donor CD8 T cells cultured with ART
patient CD4 T cells, panobinostat generally increased p24 protein in control wells
cultured with NTD CD8 T cells, relative to DMSO treatment (Fig 4-4, black
bars). In addition, there was a trend toward lower levels of p24 in wells with
either the pre-activated or resting CAR CD8 T cells, relative to the NTD CD8 T
cell wells (Fig 4-4). As the resting CD8 T cell wells were as good, if not better,
than previously activated CD8 T cells, we chose to use resting cells in a similar
assay in which only the 20nM panobinostat treatment was examined. To
determine if ART patient CD8 T cells yielded similar results to normal donor CD8
T cells, which had been used in almost all of our previous assays, we purified
autologous, ART patient CD8 T cells from the same donor as the CD4 T cells
and compared their ability to reduce p24 to normal donor, allogeneic CD8 T cells.
In contrast with the previous experiment, panobinostat did not consistently
increase p24 compared to DMSO controls in the NTD CD8 T cell cocultures (Fig
4-5, black bars). Surprisingly, in the presence of panobinostat we saw a robust
augmentation of p24 production in CAR CD8 T cell coculture wells relative to
NTD CD8 T cell control wells (Fig 4-5). Since panobinostat inconsistently
activated HIV p24 protein production and has also been shown to impair CD8 T
cell proliferation and activation, albeit less than romidepsin, we discontinued this
LRA strategy (205, 206). At the same time, promising results with the IL-15
superagonist ALT-803 demonstrated HIV-activating potential with fewer
detrimental impacts on CTL responses (205). A pilot experiment was set up
comparing the HIV-activating effects of the IL-15 superagonist (IL15 SA), 20IU/ml
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IL-2, 5ng/ul IL-7, or combinations of these drugs. Higher background levels of
p24 were observed in this experiment, but addition of the IL15 SA increased p24
in the NTD CD8 T cell control wells, compared to DMSO, IL2 or IL7 treatment
(Fig 4-5). Moreover, in all conditions except the IL2 treatment wells, CAR RNA
electroporated CD8 T cells reduced p24 relative to NTD controls (Fig 4-5). While
it is widely known that IL2 robustly activates T cells, others have reported
minimal or low HIV p24 production when IL2 was used as an LRA, somewhat
replicated by our data (205, 207). Together these assays demonstrate potential
for the SIMOA technology to determine the efficacy of CD4 CAR T cells towards
ART patient cells, but also demonstrate the need for LRAs capable of reliably
promoting HIV expression.
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Discussion

Overall, these data highlight the complexity of modeling and measuring
the latent HIV reservoir. We are not alone in this challenge, and the latency field
has experienced much difficulty and debate over which models, measurements,
and stimulatory LRAs to use (208-210). After a proof of principle analysis of CAR
CD8 T cell killing an in vitro spinoculation model with resting CD4 T cells (Fig 41), we chose to study the “natural” reservoir in ART patient cells. However, a
major downside to this is the low frequency of HIV+ CD4 T cells, making it difficult
to detect infected cells and even more difficult to detect reliable reductions in HIV
reservoirs achieved through the use of CAR T cells, whether measured by
intracellular Gag staining (Fig 4-2), HIV DNA (Fig 4-3), or p24 protein (Figs 4-3,
4-4, and 4-5).
Further complicating this is the inability of LRAs to uniformly promote HIV
activation without T cell activation and/or toxicity. Initially, promising data was
achieved with the HDACi’s we chose to employ, SAHA, Romidepsin, and
Panobinostat (177, 211, 212). However, toxicity and lack of efficacy in in vitro
assays, both in our hands and in others has diminished the outlook of those
LRAs, at least as single agents (213, 214). Despite initial promising results with
vorinostat in activating HIV mRNA in patients, its effects waned with additional
dosing and no reservoir reduction was seen (215). Romidepsin and Panobinostat
similarly did not reduce patients’ reservoirs despite increasing plasma HIV RNA
(210, 216).
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The lack of a consistent and detectable p24 signal in the absence of LRAs
demonstrates the need for better LRAs; in order to develop better models to
measure reductions in the reservoir, such as those achievable by CAR T cells,
we need to have a positive value to begin with. The caveat is that the positive
controls that have been used to induce maximum virus production, such as
αCD3/CD28 or PMA/Ionomycin, activate T cells so that they no longer represent
the quiescent, latent state that will have to be targeted in vivo.
Additional challenges to achieving robust datasets include intra-patient
and inter-patient heterogeneity in the ability of LRAs to activate all T cells from an
individual or similarly activate cells between different individuals (193, 217).
Once virus is reactivated, it is unknown what measurement is best as the
numerous assays employed to quantify the HIV reservoir show little correlation;
although the huge proportion of proviruses with internal deletions and lethal
mutations can account for some of this (192, 194, 210).
While we have some promising preliminary data utilizing an ultrasensitive
p24 ELISA, the data are a work in progress that require optimization prior to
generating publication quality results. More donors and replicates will be
required in order to gauge the variability within patients and between samples.
Nevertheless hope remains that the right combinations or new drugs could prove
efficacious (218). Recently, Descours et al. described CD32a as a biomarker for
the latent reservoir (219). This is exciting, as reservoir biomarkers could facilitate
cell sorting to enrich for HIV+ cells, and this could allow for better models of the
reservoir in which to detect reduction and killing of latently infected cells.
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Materials and methods

Plasmid construction. The CD4 zeta sequence was cloned into the pGEM and
pDA RNA expression plasmids containing the T7 promoter using the XbaI and
SalI restriction sites. pGEM was linearized with Sal1 and pDA was linearized
with SpeI prior to in vitro transcription.

In vitro transcription. RNA was created as previously described (220) using
the mMESSAGE mMACHINE T7 ULTRA transcription kit (Thermo Fisher
Scientific), according to the manufacturer’s protocols. RNA was purified using
the RNeasy Mini Kit (Qiagen).

Cell Culture. Purified CD4 and CD8 T lymphocytes were obtained by University
of Pennsylvania Human Immunology Core/CFAR Immunology Core from deidentified healthy donors or ART patients. Normal donor T cells were purified by
negative selection, unless otherwise stated below, using the RosetteSep Human
CD4+ or CD8+ T Cell Enrichment Cocktails according to the manufacturer’s
protocols (StemCell Technologies). For figures 4-3 and 4-4, the HIV donor CD4
T cells were purified by human CD4 microbeads (Miltenyi Biotec). For figure 4-5
and 4-6, HIV donor CD4 T cells were purified using the EasySep Human CD4+ T
Cell Isolation Kit (StemCell Technologies). For figure 4-5 the HIV donor CD8 T
cells were purified using the EasySep Human CD8 Positive Selection Kit II
(StemCell Technologies). T cells were cultured at 1x106 per mL in “complete
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RPMI 1640:” RPMI 1640 (Life Technologies) supplemented (ThermoFisher
Scientific) wih 10% fetal calf serum (Seradigm), 1% Penn Strep (Life
Technologies), 2 mM GlutaMax (Life Technologies), and 25 mM HEPES buffer
(Life Technologies).

CAR RNA electroporation into CD8 T cells. CD8 T cells were either left
resting or activated using αCD3/αCD28 coated Dynabeads (Life Technologies) at
a 3:1 bead to cell ratio and 100 IU/mL of recombinant human IL-2. Beads were
removed on day 5 and cells were electroporated on day 8. For electroporation,
cells were washed three times with OPTI-MEM medium (Invitrogen) and
resuspended in OPTI-MEM at 1x108 cells/ml. Subsequently, 0.1ml, or 1x107
cells, were mixed with 10μg of RNA and transferred to a 0.2 cm Gene Pulser
cuvette (BioRad) and electroporated using the BTX ECM830 Electro Square
Porator (Harvard Apparatus). The settubgs were 500V for 700μs for resting cells
or 360V for 1ms for activated cells. Cells incubated for at least 4-24 hours and
then cocultured in with the CD4 T cells.

In vitro spinoculation HIV latency assay. Spinoculation assay was performed
as previously described (198) on normal donor, human CD4 T cells. Cells were
centrifuged 1500RPM, and resuspended in 100ul per 1x10 6 cells of NL4-3 virus
supernatant, which was prepared in 293T cells by the University of
Pennsylvania’s Center for AIDS Research Viral/Molecular Core, and added to
wells of a 96 well plate. This was then centrifuged at 1,200 x g for 2 hours at RT.
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After spinoculation, cells were washed twice in CO2 independent media
(Invitrogen) and treated with 50 mg/mL Dnase I (Roche) and 10 mM MgCl2 to
remove plasmid DNA. Cells were then cultured at 4x106/ml in 300ul a 96 well
plate the presence of 1.25 mM of the protease inhibitor saquinavir (Roche) to
prevent viral spread. Cells were cultured alone or 1:1 with control or RNAtransfected CD8 T cells for 48 hours prior to staining for intracellular Gag. In the
denoted wells 1uM SAHA was added, or DMSO control.

In vitro coculture with ART patient cells. CD4 and CD8 T cells were
cocultured in 1ml of culture medium in a 48 well plate (or a 24 well plate for
Figure 2) for 16-72 hours and then wells were collected for intracellular Gag
staining, integrated HIV DNA qPCR, or HIV p24 protein analysis. E:Ts ranging
from 1:4 to 1:10 were used, depending on the number of cells available, with 1-4
million CD4 T cells cultured with 0.1-0.4 million CD8 T cells.

Integration analysis. RNA-free DNA was isolated with the Gentra Puregene
Cell Kit (Qiagen, #158745) according to the manufacturer’s guidelines. Total
genomic DNA (gDNA) was quantified through qPCR of the albumin gene.
Integrated HIV was quantified in an Alu-HIV, two-step PCR protocol (202, 221),
with the following modifications. gDNA was diluted down until 20-80% of PCR
reactions containing the given amount of gDNA were positive for HIV DNA. HIVpositive wells are quantified through a presence-absence qPCR assay. These
measurements follow the Poisson distribution, which can be used to calculate the
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number of HIV copies per given amount of gDNA independent of a standard
curve (222). To control for linear amplification from unintegrated HIV, 8-wells
containing only the HIV-specific primer were included for each measured sample,
and HIV-positives wells with a cycle-threshold (Ct) falling within 2 standard
deviations of the average Ct from Linear-HIV wells were excluded. Using this
method, we can calculate 2-fold changes in integrated HIV-DNA.

Ultrasensitive p24 detection. Cells pellets were lysed in 1% triton x-100 in PBS
and diluted according to a protocol supplied by Bonnie Howell (Merck & Co, Inc.).
The HIV p24 Gag protein was measured using the p24 single molecule array
using the Simoa HD-1 Analyzer (Quanterix) following the manufacturer’s
instructions. Each sample was measured in duplicate and concentration
calculated based on a standard curve. The average concentration of two
replicates for each sample was reported. The accurate detection range was
0.008pg/ml to 39.5pg/ml.

Flow cytometry. CD4 CAR surface expression was monitored with mouse anti
human CD8-FITC and anti-human CD4 APC antibodies (BD biosciences). Cells
were visualized on a LSR II flow cytometer (BD Biosciences) and analyzed
using Flowjo software (Tree Star). HIV was detected intracellular p24 Gag with
the KC57 anti-Gag-RD1 antibody (Beckman Coulter) and the Invitrogen Fix and
Perm buffers, according the manufacturers’ instructions.
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Figures:

Figure 4-1. CD4 CAR CD8 T cells reduce HIV Gag in a spinoculation model of HIV
latency. Intracellular Gag staining performed after a 48 hour coculture on resting
spinoculated CD4 T cells either (A) left uninfected (B) HIV-infected (C) cultured with 1uM
SAHA (D) cultured 1:1 with autologous nontransfected (NTD) CD8 T cells and 1uM
SAHA (E) cultured 1:1 with CD4 CAR RNA transfected CD8 T cells and 1uM SAHA or
(F) cultured 1:1 with CD4 CAR RNA transfected CD8 T cells.
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Figure 4-2. Intracellular Gag staining is not sensitive enough to detect CAR T cell
reduction of HIV in ART patient CD4 T cells. CD4 T cells were isolated from ART
patient PBMCs and cultured for 16 hours alone or in the presence of nontransduced or
CD4 CAR transduced allogeneic, normal donor CD8 T cells at a 1:10 E:T ratio.
Additionally, 0.1mM C7A or DMSO control was added or a 3:1 ratio of αCD3/αCD28
coated beads. After 16 hours, the wells were collected and stained for (A) intracellular
Gag and (B) CD69 expression.
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Figure 4-3. Integrated HIV DNA is more readily detected in ART patient cells. CD4
T cells were isolated from ART patient PBMCs and cultured alone or in the presence of
allogeneic, normal donor unmodified control CD8 T cells (NTD), lentivirally transduced
CAR CD8 T cells (preactivated), or RNA-transfected, resting CAR CD8 T cells at a 1:4
E:T ratio. In addition, either 40uM romidepsin or ART (efavirenz, saquinavir, and
raltegravir, 1uM each) was added to designated wells. After 24hours, wells were
collected and cells were lysed for analysis of integrated HIV DNA by qPCR, reporting the
integrated HIV DNA copies per million cells.
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Figure 4-4. Panobinostat increases HIV p24 Gag compared to DMSO. CD4 T cells
were isolated from ART patient PBMCs and cultured or in the presence of
nontransfected (NTD) or CD4 CAR transfected allogeneic, normal donor CD8 T cells at
a 1:10 E:T ratio that were either left resting or preactivated with αCD3/αCD28 coated
bead. Either vehicle control (DMSO) or the indicated concentrations of panobinostat
were added to the wells at the time of coculture. After 72 hours the wells were collected
and cell lysate analyzed for p24 Gag.
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Figure 4-5. Panobinostat activates robust HIV p24 Gag production in the presence
of CAR CD8 T cell. CD4 T cells were isolated from ART patient PBMCs and cultured or
in the presence of nontransfected (NTD) or CD4 CAR transfected CD8 T cells at a 1:10
E:T ratio. CD8 T cells were either isolated from an allogeneic, normal donor (ND 8s) or
from the autologous CD4 T cell donor (HIV 8s). Either vehicle control (DMSO) or the
20nM panobinostat was added to the wells at the time of coculture. After 24 or 72
hours, the wells were collected and cell lysate analyzed for p24 Gag.
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Figure 4-6. IL15 SA activates HIV relative to DMSO and allows for detection of CAR
CD8 T cell killing. CD4 T cells were isolated from ART patient PBMCs and cultured or
in the presence of nontransfected (NTD) or CD4 CAR transfected allogeneic, normal
donor CD8 T cells at a 1:5 E:T ratio. Either vehicle control (DMSO) or 1.7nM IL-15
superagonist (IL15 SA), 20IU/ml IL-2, 5ng/ul IL-7 was added to the wells at the time of
coculture. After 24 hours, the wells were collected and cell lysate analyzed for p24
Gag.

145

CHAPTER 5 – Conclusions and Future Directions

Given the relatively recent discovery of HIV-1 and the extremely complex
biology of the virus, it is awe-inspiring to consider how rapidly the ACT efforts for
HIV progressed. Less than a decade after the initial reports that CD8 T cells
both contribute to control over HIV and shape virus escape, efforts were
underway to augment host CTL responses using ACT (49). Unfortunately, HIV
escape from autologous, expanded HIV-specific CTLs and a lack of efficacy of
the transferred cells, combined with the concomitant development of highly
effective ART regimens, largely halted the pursuit of these strategies for HIV
treatment. Among these trials were the initial CD4-zeta CAR T cell infusions,
which were found to be safe but did not reduce the HIV reservoir consistently or
durably enough to warrant infusion into larger cohorts of patients (42, 43).
Nevertheless, T cell based ACT approaches are still being explored by a
handful of HIV laboratories around the world in the hopes that augmented control
will be achieved with new technologies. Diverse T-cell expressed antiviral
transgenes, including antisense RNA and dominant negative HIV Tat and Rev
proteins, have made their way to the clinic, but have largely been unsuccessful
(49). On the other hand, the recent, promising clinical trial results using CCR5
ZFN-edited autologous CD4 T cells have renewed interest in the role that geneedited T cells may play in a functional HIV cure (88). At the same time another
clinical trial is underway using an alternative method to protect CD4 T cells, with
a GP41-based C34 peptide fused to the N terminus of the CXCR4 HIV
coreceptor (NCT03020524). These strategies hold the possibility of protecting
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critical populations of natural patient effector and helper T cells to augment their
functionality and mimic elite controller phenotypes with long-term suppression in
the absence of ART.
We hypothesized that the most promising avenue for T cell based ACT
would be through re-engineering CARs with increased survival and effector
potential to target HIV. Taking advantage of many scientific advances made in
the ACT field during the 15 years following the initial CD4-zeta CAR clinical trials,
we undertook a project to re-design this CAR in an effort to augment control over
HIV, with the ultimate goal of generating a clinically viable therapy. Throughout
this project we learned many lessons and identified many avenues that remain
underexplored regarding these CD4 CARs, which will be discussed below.

Major lessons learned

Augmenting CAR expression greatly enhances control over HIV replication.
As discussed in Chapter 2, CAR expression was greatly improved by a
combination of substituting a lentiviral expression vector for the MMLV-based
vector and the EF1α promoter for the PGK promoter. The enhanced control over
HIV replication in culture achieved by these two, simple modifications was
surprising, with CAR CD8 T cells that could now control HIV down to a 1:50 E:T
ratio when the original vector lost control past a 1:1 ratio. However, other factors
clearly play important roles as well. For instance, swapping the CD8α
transmembrane (TM) for the CD4 TM domain augmented control while slightly
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reducing CAR surface expression. While we demonstrated less infection in the
CAR T cells containing the CD8α TM domain, it is possible that this benefit can
also be attributed to dimerization and signaling differences that enhance CAR T
cell functionality.

The 4-1BB costimulatory domain promotes effective in vivo control over
HIV in humanized mice, despite poorer control in vitro. Based on our in vitro
studies, we were fairly certain that a CAR containing CD28 (28z) was the most
promising clinical candidate due to its potent in vitro control and cytokine
production, relative to 4-1BB containing CARs (BBz). Nevertheless, clinical
evidence as well as mouse tumor models supported the use of 4-1BB in tumorspecific CAR T cells, so we decided to include it in our humanized mouse models
of HIV infection (16, 31, 54). To our surprise, 4-1BB containing CD4 CARs
provided superior control over HIV in two different scenarios: early on in an HIV
prevention model in which CAR CD8 T cells were injected prior to HIV, and also
durable control in an HIV treatment model. Early on in the HIV prevention model,
higher BBz CAR T cell counts and lower plasma HIV RNA were observed,
relative to 28z CAR T cells. With time (and antigen exposure), 28z T cells caught
up and similar viral loads were observed by the experimental endpoint. In our
HIV treatment model, we had similar numbers of BBz and 28z CD8 T cells early
on and again saw similar levels of control when the BBz and 28z CAR T cell
numbers matched. However, as BBz out-proliferated the 28z CD8 T cells, we
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saw maintenance of control by BBz only, whereas 28z then lost control to the
extent that the viral loads matched NTD mice.
We further observed an antigen-independent survival and proliferation of
the BBz CAR T cells, but not the 28z cells, in uninfected mice. This was not
entirely surprising, as antigen independent cell survival was reported in vitro for
the CD19-BBz CAR (16). There is a lack of published literature describing the
effects of BBz CAR T cells in an antigen independent setting, such as in tumor
free mice, though it is highly unlikely these experiments have not been
performed. For example, as part of a study utilizing SS1 mesothelin-directed
CARs members of the June lab compared survival of SS1 CAR T cells containing
4-1BB, CD28, and ICOS in both tumor-injected and tumor-free mice, but only
published data on tumor free mice injected with ICOS CAR T cells (223).
However, they saw a pattern similar to us, with enhanced survival of SS1-BBz
CAR T cells in the tumor free mice, relative to both the 28z and ICOSz mice
(data unpublished).
The ability of CAR T cells to survive long-term, or at least temporarily, in
the absence of antigen is a critical therapeutic consideration, as patients will
likely be on ART when CAR T cells would be infused. This survival benefit may
outweigh the effector phenotype advantage that CD28 theoretically imparts.
Zhao et al. found that CD28 intracellular costimulatory domains promote greater
functional potential in CAR T cells, but 4-1BB is critical for survival (57).
Interestingly, both persistence and anti-tumor functionality could be increased in
the 28z CAR T cells by including the 4-1BBL as part of a bicistonic vector, but not
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by a third generation CAR expressing both CD28 and 4-1BB intracellular
costimulatory domain. It would be worthwhile to determine if this combination
could similarly augment control over HIV in vivo with our CD28 containing CD4
CAR T cells.

CAR expression renders T cells susceptible to HIV infection. While a handful
of papers have recently been published that describe the capacity of the CD4
CAR to render T cells susceptible to HIV infection, at the time this project was
initiated the published accounts of the original clinical CD4-zeta CAR did not
address this issue. In fact, the only source available at that time that even
mentioned the CD4 CAR facilitating infection was the clinical protocol written by
Cell Genesys, the company that manufactured the retroviral vector utilized in the
trial. A few short sentences stated:

“The theoretical possibility exists that these transduced cells will become
susceptible to HIV infection, as the virus gains entry into cells using the CD4
glycoprotein as a receptor. Consequently, studies were designed to test the
infectibility of the [CD4-zeta] CD8+ T cells in vitro. Using two different strains of
virus (HIV-1 IIIB and JR-CSF) in 7-day cultures, preliminary results have
detected no evidence of infection in genetically modified cells based on the
absence of p24gag in the supernatant (data on file, Cell Genesys, Inc.).”
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In contrast to this report, early in my thesis work it became apparent that
CD4 CAR expression facilitated infection of CD8 T cells. At first I concluded the
opposite, as cell-free virus never resulted in a productive HIV infection, as
determined by an intracellular Gag signal in the CD4 CAR CD8 T cells that
increased in frequency over time. However, once I established a coculture
system in which CAR-transduced effector cells were diluted down to low levels
with HIV-infected CD4 T cells, it became apparent that an E:T ratio could be
reached such that the CAR CD8 T cells became infected. This observation
promoted an entire extension of the project, protecting CAR T cells, which was
discussed in Chapter 3. Moreover, we discovered that the mechanism by which
these CAR CD8 T cells become infected is fairly complex and difficult to tease
apart in vitro, as we could not prevent infection using either Δ32 CD8 T cells or
scFv CAR T cells. Whether this is a byproduct of our in vitro coculture assays, or
an inevitable consequence of CAR T cells fusing their membranes with HIVinfected target cells during killing remains to be determined.

Protecting CAR T cells with CCR5 ZFNs may be beneficial, but more data is
required to conclude consistent benefits. In general, utilizing CCR5 ZFNs to
protect our CD4 CAR CD8 T cells did not drastically alter the outcomes in terms
of cell counts or viral control. While pre-treating CD8 T cells with CCR5 ZFNs
resulted in significantly reduced viral loads for the MMLV CD4-zeta clinical trial
CAR in the HIV prevention model, similar treatment had no benefit for the BBz or
28z CAR T cells in either model. In the HIV treatment model the 28z cohort
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succumbed to high viral loads, so based on the prevention model results we
could predict to see a window of opportunity in which we would detect a benefit
from ZFNs, yet no such benefit was seen. Long et al. reported higher levels of
exhaustion in CAR T cells containing both CD28 and CD3-zeta costimulatory
domains, compared to those containing solely CD3-zeta (58). It is possible that
negative in vivo effects of utilizing a 28z CAR mitigated the antiviral effects of
CCR5 ZFNs, since protecting dysfunctional CAR T cells would not promote
better control over HIV.
ZFN treatment also did not enhance CAR CD8 T cell counts in the HIV
prevention model, but did enhance both BBz and 28z CAR CD8 T cell counts in
the HIV treatment model, albeit to a nonsignificant extent. Importantly, we do not
have conclusive evidence whether ZFN modified CAR T cells truly enriched in
their disrupted alleles over time, or simply did not succumb to the negative
selection effects that occurred in the absence of HIV. A longer term experiment
where CD4 T cells could be replenished, such as a BLT mouse model, may be
beneficial in answering if the trends we saw in our two mouse experiments will be
consistent over a longer period of time and in the absence of overt GVHD.

Future directions

The greatly augmented control we have achieved through re-engineering
the clinical trial CD4-zeta CAR provides much optimism to revisit the clinic and
examine to what extent the improved CAR can provide durable control over HIV
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in patients. However, many unanswered questions remain; we have only
breached the tip of the iceberg in terms of analyzing the functionality of CD4 CAR
T cells in vivo. While we chose to use an NSG hu-T cell mouse model for its
simplicity and the ability to inject fully human CD4 T cells that were grown using a
similar method to the CAR T cell trials, we also acknowledge that this model has
many drawbacks for modeling HIV. In particular, it is a short-term model due to
the inability to regenerate new CD4 T cells once depleted by HIV or on the
contrary, if a therapy works then the human T cells expand rapidly and result in
the onset of GVHD.
Moving forward, better animal models of long-term CAR T cell trafficking,
survival, and control could be developed. We favor the use of the bone marrowliver-thymus (BLT) mouse model or the simian/human immunodeficiency virus
(SHIV) non-human primate (NHP) model. In the BLT mouse model, the T cell
responses are surprisingly recapitulative of the human T cell response to HIV
(224), and Colby Maldini in the Riley lab has shown that BLT-derived splenic
CD8 and CD4 T cells can be activated and transduced to express the CD4 CAR,
and then exhibit functionality in terms of cytokine production and control over HIV
in vitro (unpublished data). Recently, George Shaw’s lab improved SHIV design
to generate a virus capable of replicating to high titer in rhesus macaques (225).
SHIV models would allow us to utilize our human CD4-based CAR in long-term
NHP studies, ideal for studying HIV functional cure therapies in the absence of
GVHD. Another benefit of using NHP is the ability to assess anti-CAR antibody
development in immune-competent animals over a number of years, which could
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arise in response to a foreign peptide created by fusing the CD4 extracellular
domain to the CD8α extracellular hinge.
These improved animal models would allow us to analyze a variety of
critical parameters pertaining to CAR T cell phenotype and efficacy. To begin,
we did not analyze CAR T cell trafficking in the NSG mice beyond peripheral
blood and spleen. It will be informative to follow CAR T cell trafficking patterns
by analyzing numerous lymphoid and non-lymphoid tissues. It has been
demonstrated in HIV patients that CD8 T cells fail to enter lymphoid follicles or
fail to upregulate CTL function (226, 227). Whether or not CD4 CAR T cells can
traffic to lymphoid follicles or whether that is required for suppression of the virus
in vivo remains unknown. New technologies, including whole-body immunoPET
scanning, could provide a non-invasive method for tracking CAR T cell therapy in
NHPs over time (228).
Sustained cytotoxic effector functions are critical for suppressing HIV in
the absence of ART, as it is unlikely CAR T cells will be able to rid the body of
every single cell harboring replication-competent virus. Thomas Burn, a previous
rotation student in the Riley lab saw both upregulation of PD-1 and sustained
expression on PD-1 in CD4 CAR-transduced CD8 T cells, but not in CD8 T cells
expressing the PG9 scFv based CAR (unpublished data). A more
comprehensive analysis of the in vitro and in vivo phenotypes of CAR T cells,
including exhaustion and activation markers and memory cell phenotyping is
currently lacking. Nevertheless, the survival advantage we see with our CD4
BBz CAR T cells is consistent with the recent report describing the central
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memory phenotype ascribed to 4-1BB expression in CAR T cells and the effector
memory phenotype ascribed to CD28-containing CAR T cells (229). In addition
to phenotyping with surface antibodies or measuring intracellular proteins with
western blots, we could simultaneously perform RNA expression analysis on
CD4 CAR transduced T cells after transduction in vitro and after long-term
survival in vivo. We could use the findings of these studies to inform future
therapeutic models such as determining if checkpoint blockade could augment
CD4 CAR T cell function.
As demonstrated in Chapter 4, modeling the HIV reservoir in vitro is very
challenging, and BLT and SIV/SHIV models could greatly inform our
understanding of CD4 CAR T cell treatment in the context of ART and in
preventing HIV rebound once ART has been removed (189, 230). Moreover
these animal models could allow us to determine whether virus escape from the
CD4 CAR is possible over a period of several months or years. We hypothesize
that escape from CD4 binding would impose a detrimental fitness cost to the
virus, as CD4-independent viruses have previously been described as
neutralization sensitive and intrinsically unstable (231). Nevertheless a few
reports of CD4-independent isolates of HIV have been described (232, 233).
Moreover, the pressure exerted by CTLs expressing a CD4-based CAR may
force virus evolution in a manner very different than natural HIV infection. Longterm animal experiments could track the evolution of HIV quasispecies over time
in the presence of CAR T cells and could test for escape over several years.
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As mentioned throughout this thesis, an area that requires much more
work regards protecting CAR-transduced T cells. At the present time, it is
unclear to what extent protecting CAR T cells is beneficial in vivo and what
protection method or methods are best. Since both Δ32 and scFv-based CAR
CD8 T cells were susceptible to HIV infection, it appears that either CAR T cells
can exogenously uptake the necessary cell entry components or that infection via
an HIV-specific CAR may not require the traditional receptor plus coreceptor
infection pathway. Along these lines, Aucher et al. reported in vitro CD4 uptake
by CD8 T cells from HIV-infected patients, which could then induce syncytia
formation in culture (234). Moreover, the immunologic and virologic synapse
created by CAR-transduced CTLs fusing with their targets may look very different
than the host membranes that HIV typically encounters upon natural infection. A
recent CRISPR screen identified proteins besides CD4 and CCR5, including cell
adhesion molecules, important for HIV cell-cell transmission (235). One could
imagine that in the context of high affinity CAR binding plus the contributions of
the immunological synapse, the strict requirement for coreceptor, or even CD4,
might be bypassed.
Finally, the observed negative selection of CCR5-disrupted cells in our
mouse model warrants further investigation to determine if this was a fluke
observation, specific to the NSG mouse model we used, or a true phenotypic
consequence of losing CCR5 (or CXCR4, as described below). As mentioned
previously, Perez et al. had a decreased proportion of CCR5 disrupted alleles in
the uninfected mice at the endpoint of their mouse experiment (83). Similar to
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our observations that CCR5 disruption decreased to almost 0% in our uninfected
animals, a report using CXCR4-directed ZFNs in CD4 T cells saw the CXCR4
disruption drop from 16% to almost 0% in uninfected NSG mice (138). In direct
contrast, two additional reports using CXCR4-targeting ZFNs, one of which
simultaneously edited CD4 T cells with ZFNs directed at CCR5, did not see the
proportion of disrupted CXCR4 or CCR5 alleles drop in the uninfected mice
relative to the infusion product (137, 139). No obvious methodological
differences exist in mouse strain or experimental timeline, and all other reports
(besides ours) utilized an Ad5/F35 vector to introduce the ZFNs. Moreover, the
same CCR5 ZFN proteins used in the Perez study (which saw a decrease in
CCR5 disrupted alleles) were utilized in the Didigu study (which saw stable levels
of CCR5 disruption in the context of no HIV and dual ZFN treatment), so this
effect is not specific to different ZFN designs. Natural deletion of CCR5 surface
expression by the Δ32 mutation is not similarly detrimental in humans, as T cells
can be readily isolated from people with this mutation. Nevertheless, differential
gene expression has been found to be associated with the Δ32 mutation (236).
Moreover, the Δ32 mutation uniformly occurs in these people, so they don’t have
the potential for competition between WT and Δ32 cells that could result from
partial CCR5 deletion with ZFNs. In summary, further animal models applying
the coreceptor-targeting ZFNs will be required to conclusively determine if the
edited cells survive and are phenotypically normal.
Since ART can almost completely suppress HIV replication in the majority
of patients, the bar is set high for explorative therapies including CAR T cells.
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Unless these new therapies can durably suppress HIV for months or years in the
absence of ART, their development will not progress beyond small pilot studies in
humans. While major strides have been made in the field of T cell engineering
for adoptive therapy, including demonstrations of safety and feasibility, no clinical
trial has resulted in durable and consistent control over HIV-replication in the
absence of ART. Combinatorial approaches that produce HIV-resistant cells and
simultaneously augment HIV-specific CD4 and CD8 T cell immunity will likely
have greater effects on long-term control. Identifying what T cell subsets afford
the greatest proliferative capacity and transgene expression over time in vivo,
such as naïve or stem cell memory phenotypes, may similarly augment
suppression of HIV. The data presented throughout this thesis provide evidence
that CD4-based CARs could play an important role in redirecting T cells,
improving immune-mediated control, and achieving a functional cure for HIV.
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